Drug Overdose Fatality Surveillance System (DOFSS) 2017 Annual Technical Report

Released: June 2020

Sarah L. Hargrove, MS Patrick J. Ward, MPH Lane G. Mitchell, BPH Terry L. Bunn, PhD

Kentucky Injury Prevention and Research Center, bona fide agent for the Kentucky Department for Public Health
University of Kentucky
333 Waller Avenue, Suite 242
Lexington, Kentucky 40504-2915
(859) 257-4954
www.kiprc.uky.edu





Table of Contents

DOFSS OVERVIEW	7
Data Sources	7
Funding	7
Acknowledgments	7
Survey	7
Suggested Citation	7
EXECUTIVE SUMMARY	8
HIGHLIGHTS	9
DEFINITIONS	10
2017 KENTUCKY DRUG OVERDOSE FATALITY SURVEILLANCE DATA	13
OVERALL DATA	13
Table 1. Overall Kentucky Drug Overdose Fatality Data, 2017	13
Table 2. Overall Demographic and Socioeconomic Factors Among Drug Overdose Decedents in Kentucky, 2017	14
Table 3. Place of Injury Among Drug Overdose Decedents in Kentucky, 2017	15
Table 4. Place of Death Among Drug Overdose Decedents in Kentucky, 2017	15
POST-MORTEM TOXICOLOGY RESULTS	
Table 5. Drug Classes Detected Among Drug Overdose Decedents in Kentucky, 2017	16
Table 6. Most Frequent Drugs Detected Among Drug Overdose Decedents in Kentucky, 2017	
Figure 1. Total Number of Drugs Detected Per Drug Overdose Decedent in Kentucky, 2017	19
Table 7. Percentile of Total Number of Drugs Detected Per Drug Overdose Decedents in Kentucky, 2017	
Table 8. Most Frequent Drugs Detected Among Kentucky Drug Overdose Decedents with Less Than Four Total Drugs in Post-Mortem Toxicology, 2017	20
Figure 2. Most Frequent Drugs Found in Combination with Commonly Detected Drugs Among Drug Overdose Decedents in Kentucky, 2017	21
Table 9. Most Common Two-Drug Combinations Detected Among Drug Overdose Decedents in Kentucky, 2017.	26
Table 10. Most Common Three-Drug Combinations Detected Among Drug Overdose Decedents in Kentucky, 2017	27
Table 11. Most Common Four-Drug Combinations Detected Among Drug Overdose Decedents in Kentucky, 2017	28
Figure 3. Median Blood Concentration, Interquartile Range, and Therapeutic Range of Top Therapeutic Drugs Identified Among Drug Overdose Decedents in Kentucky, 2017	29
Table 12. Drug Classes Identified Among Drug Overdose Decedents in Kentucky by Suicide and Accidental Manners of Death, 2017	32





DRUG OVERDOSE FATALITY DEMOGRAPHICS	33
Table 13. Most Frequent Drugs Identified Among Drug Overdose Decedents in Kentucky by Gender, 2017	33
Table 14. Most Frequent Drugs Identified Among Drug Overdose Decedents in Kentucky by Age Group, 2017	34
Table 15. Most Frequent Drugs Identified Among Drug Overdose Decedents in Kentucky by Race, 2017	35
DRUG OVERDOSE FATALITY SOCIOECONOMIC FACTORS	36
Table 16. Most Frequent Drugs Identified Among Drug Overdose Decedents in Kentucky by Education Level, 2017	36
Table 17. Most Frequent Drugs Identified Among Drug Overdose Decedents in Kentucky by Marital Status, 2017	37
Table 18. Most Frequent Industries Identified Among Drug Overdose Decedents in Kentucky, 2017	38
KENTUCKY RESIDENT DRUG OVERDOSE FATALITY COUNTS AND RATES	39
Table 19. Kentucky Resident Drug Overdose Fatality Counts and Rates by County, 2016–2017	
Figure 4. Kentucky Resident Drug Overdose Fatality Rates per 100,000 Population by County, 2016	43
Figure 5. Kentucky Resident Drug Overdose Fatality Rates per 100,000 Population by County, 2017	43
Table 20. Kentucky Resident Drug Overdose Fatality Counts and Rates by Kentucky Area Development District (ADD), 2016–2017	44
Table 21. Kentucky Resident Drug Overdose Fatality Counts Involving Scheduled Controlled Substances and Unscheduled Drugs by Kentucky Area Development District (ADD), 2017	45
Table 22. Kentucky Resident Drug Overdose Fatality Counts Involving Specific Drugs by Kentucky Area Development District (ADD), 2017	46
Figure 6. Kentucky Resident Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016	47
Figure 7. Kentucky Resident Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017	47
Figure 8. Kentucky Resident Schedule I-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016	
Figure 9. Kentucky Resident Schedule I-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017	48
Figure 10. Kentucky Resident Schedule II-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016	
Figure 11. Kentucky Resident Schedule II-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017	
Figure 12. Kentucky Resident Schedule III-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016	50
Figure 13. Kentucky Resident Schedule III-Involved Drug Overdose Fatality Rates per 100,000 Population by	50





	Figure 14. Kentucky Resident Schedule IV-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016	.51
	Figure 15. Kentucky Resident Schedule IV-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017	51
	Figure 16. Kentucky Resident Unscheduled-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016	.52
	Figure 17. Kentucky Resident Unscheduled-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017	.52
	Figure 18. Kentucky Resident Heroin-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016	. 53
	Figure 19. Kentucky Resident Heroin-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017	. 53
	Figure 20. Kentucky Resident Fentanyl-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016	54
	Figure 21. Kentucky Resident Fentanyl-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017	54
	Figure 22. Kentucky Resident Heroin and Fentanyl-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016	55
	Figure 23. Kentucky Resident Heroin and Fentanyl-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017	55
	Figure 24. Kentucky Resident Methamphetamine-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016	
	Figure 25. Kentucky Resident Methamphetamine-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017	
E١	/IDENCE FOUND AT SCENE AND/OR AUTOPSY OF DRUG OVERDOSE DECEDENTS	. 57
	Table 23. Most Frequent Drugs Detected in Post-Mortem Toxicology Test Results of Drug Overdose Decedents in Kentucky with Drug Paraphernalia Recovered at Scene and/or Autopsy, 2017	57
	Table 24. Most Frequent Drugs Detected in Post-Mortem Toxicology Test Results of Drug Overdose Decedents in Kentucky with Illicit Drugs Recovered at Scene and/or Autopsy, 2017	. 58
	Table 25. Most Frequent Drugs Detected in Post-Mortem Toxicology Test Results of Drug Overdose Decedents in Kentucky with Prescription Drugs Recovered at Scene and/or Autopsy, 2017	59
	Table 26. Drug Overdose Decedents in Kentucky with Nonmedical-Related Needle or Track Marks Identified and the Body Location of the Marks, 2017	60
	Table 27. Decedent History of Substance Use by Evidence Recovered at Scene and/or Autopsy, 2017	. 61
	Table 28. Evidence Recovered at Scene and/or Autopsy that Indicates Route of Administration, 2017	. 61
	Table 29. Most Frequent Drugs Detected in Post-Mortem Toxicology Testing Results of Drug Overdose Decedents in Kentucky with Evidence of Injection, 2017	62





Table 30. Most Frequent Drugs Detected in Post-Mortem Toxicology Testing Results of Drug Operation Decedents in Kentucky with Evidence of Ingestion, 2017	
Table 31. Most Frequent Drugs Detected in Post-Mortem Toxicology Testing Results of Drug Decedents in Kentucky with Evidence of Snorting, 2017	
Table 32. Most Frequent Drugs Detected in Post-Mortem Toxicology Testing Results of Drug Operation Decedents in Kentucky with Evidence of Smoking, 2017	
Table 33. Top Identifiable Prescription and Over-the-Counter (OTC) Drugs Found at Scene and Among Drug Overdose Decedents in Kentucky, 2017	
MEDICAL AND SOCIAL HISTORY OF DRUG OVERDOSE DECEDENTS	67
Figure 26. Other Significant Medical Conditions Contributing to Death of Drug Overdose Dece 2017	•
Table 34. Medical Conditions of Drug Overdose Decedents in Kentucky, 2017	68
Figure 27. Body Mass Index (BMI) Range for Drug Overdose Decedents in Kentucky, 2017	71
Table 35. Drug Overdose Decedent Body Mass Index (BMI) Percentiles	71
Table 36. Circumstances and History of Drug Overdose Decedents in Kentucky, 2017	72
Table 37. Most Frequent Drugs Detected in Post-Mortem Toxicology Test Results of Drug Ove in Kentucky with History of Substance Use, 2017	
Figure 28. Demographics of Drug Overdose Decedents in Kentucky with History of Substance	Use, 201775
Table 38. Suicide and Accidental Manners of Death Among Drug Overdose Decedents in Kent of Substance Use, 2017	
Table 39. Opioid-Involved Drug Overdoses Among Drug Overdose Decedents in Kentucky wit	
Table 40. Most Frequent Drugs Detected in Post-Mortem Toxicology Test Results of Drug Ove in Kentucky with History of Mental Illness, 2017	
Figure 29. Demographics of Drug Overdose Decedents in Kentucky with History of Mental Illn	ess, 2017 ^{1–2} 78
Table 41. Suicide and Accidental Manners of Death Among Drug Overdose Decedents in Kent of Mental Illness, 2017	
PRESCRIPTION DRUG MONITORING PROGRAM (PDMP) HISTORY OF DRUG OVERDOSE DECEDEN	ITS80
Table 42. Most Frequent Schedule II–V Controlled Substances Dispensed to 2017 Drug Overd Kentucky, Three-Year Period Prior to Death Year (1/1/2015–12/31/2017)	
Table 43. Number of Drug Overdose Decedents with an Active Schedule II–V Prescription Dispose Detected in Post-Mortem Toxicology, Prescription Active 180 Days Prior to Death, 30 Days Property Day of Death	ior to Death, and
Table 44. Most Frequent Schedule II–V Opioids (Excluding Buprenorphine/Naloxone) Dispens Overdose Decedents with Illicit Opioids Detected in Post-Mortem Toxicology, Three-Year Per 12/31/2017)	•





	Table 45. Number of Drug Overdose Decedents with Illicit Opioids Detected in Post-Mortem Toxicology with an Active Schedule II–V Opioid Prescription (Excluding Buprenorphine/Naloxone), Prescription Active 180 Days Prior to Death, 30 Days Prior to Death, and Day of Death	83
	Table 46. Most Frequent Schedule II–V Controlled Substances Detected in Post-Mortem Toxicology of 2017 Drug Overdose Decedents in Kentucky Without a Prescription Identified, Three-Year Period Prior to Death Year (1/1/2015–12/31/2017)	84
DO	DFSS QUALITY CONTROL MEASURES	85
	Table 47. Number and Percentage of Drug Overdose Fatality Coroner Investigation Reports Received for DOFSS, 2015–2017	
	Table 48. Identification of Specific Drug Involvement Using a Multi-Source Surveillance System, 2016–2017	85





DOFSS OVERVIEW

Kentucky's Drug Overdose Fatality Surveillance System (DOFSS) is a comprehensive database that utilizes multiple sources to enhance the Commonwealth's analytical capacity to identify and characterize drug overdose fatalities. Without a centralized death investigation system, Kentucky has no single agency that is responsible for collecting drug overdose fatality data. DOFSS bridges the gaps by inputting drug overdose decedent data into a centralized database—a comprehensive multi-source database that captures additional information on drug overdose fatalities and identifies emerging trends and patterns of drug use that may not be readily identified through analysis of data from a single source.

Data Sources

DOFSS utilizes the following data sources:

- Vital statistics death certificates (with National Center for Health Statistics ICD-10 coding)
- Medical examiner autopsy reports
- Coroner investigation reports
- Post-mortem toxicology reports
 - o Post-mortem toxicology reports were not identified in 106 cases
- Kentucky All Schedule Prescription Electronic Reporting (KASPER) records
 - o KASPER reports were identified in 1,015 cases

Data in DOFSS is provisional and subject to change. Data for this report was analyzed on March 12, 2019.

Funding

This report was supported by Cooperative Agreement Number 1 NU17CE924971-01-00, funded by the Centers for Disease Control and Prevention and awarded to the Kentucky Injury Prevention and Research Center as the bona fide agent for the Kentucky Department for Public Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services. The REDCap database used to enter DOFSS data is supported by a grant from the Center for Clinical and Translational Research (NIH CTSA UL1TR000117).

Acknowledgments

We would like to thank the Kentucky Department for Public Health, Office of Vital Statistics for access to death certificate records, the Office of Inspector General for access to KASPER data, the Office of the State Medical Examiner for access to autopsy reports and post-mortem toxicology reports, all county coroners for access to coroner reports, and the project managers of the grant supporting this report for their guidance.

Survey

Please take a moment to complete our brief survey regarding this report: https://uky.az1.qualtrics.com/jfe/form/SV ODsbNMuz3ogGKqN.

Suggested Citation

Hargrove SL, Ward PJ, Mitchell LG, Bunn TL. "Kentucky Drug Overdose Fatality Surveillance System 2017 Annual Technical Report." Kentucky Injury Prevention and Research Center. June, 2020.





EXECUTIVE SUMMARY

The Kentucky Injury Prevention and Research Center (KIPRC), located at the University of Kentucky College of Public Health and a bona fide agent for the Kentucky Department for Public Health, in collaboration with the Kentucky Office of the State Medical Examiner and county coroner offices, is pleased to present the 2017 Kentucky Drug Overdose Fatality Surveillance System (DOFSS) annual technical report.

The findings of the 2017 report indicate progress in the prevention of drug overdose deaths in Kentucky. There was a 15% decrease in drug overdose fatalities involving oxycodone, a 15% decrease in hydromorphone-involved deaths, a 7% decrease in deaths involving alprazolam, a 5% decrease in those involving heroin, and a 3% decrease in those involving gabapentin. Concurrent with these decreases was a 50% increase in drug overdose deaths involving fentanyl. While major strides were achieved in preventing drug overdose deaths in 2017, sustained substance use disorder prevention, treatment, and recovery programs are still critically needed at the state and community levels.

Opioid prescribing stewardship programs in emergency departments, reduced availability of prescription opioids, timely access to substance use disorder treatment, and other primary drug overdose prevention programs in both the general community and in the workplace have helped reduce the number of drug overdose deaths.

To reduce the number of drug overdose deaths involving fentanyl, community secondary prevention programs, such as fentanyl testing strip distribution programs and naloxone distribution programs, may help save lives and prevent drug overdose fatalities.

Tertiary prevention strategies, such as high-quality sustained recovery residence availability and full integration of institutionalized individuals back into local communities, are also needed to help reduce relapse of individuals with substance use disorders.

www.FindHelpNowKY.org, developed by KIPRC as the bona fide agent for the Department for Public Health, is a resource for health professionals, public safety professionals, and for the general public that provides a directory of substance use disorder treatment facilities with available openings. A resource section with information on substance use disorders and treatment is also included in www.FindHelpNowKY.org.

Our heartfelt sympathies are tendered to the families, friends, and colleagues of those individuals with substance use disorders and others who have died from drug overdoses. Our hope is that primary, secondary, and tertiary drug overdose prevention programs, along with substance use disorder treatment and recovery strategies, will hasten a reduction in the number of individuals with substance use disorders and in the number of drug overdose fatalities in Kentucky.

Sincerely,

Terry Bunn, Director

Kentucky Injury Prevention and Research Center





HIGHLIGHTS

- There were 1,561 drug overdose deaths overall for the state of Kentucky; 1,456 of the deaths were Kentucky residents whose death occurred in state, Table 1.
- Of 1,455 deaths with toxicology results, the most common drug classes involved were opioids (88%), benzodiazepines (43%), and amphetamines (33%), Table 5.
- 3. The most frequently detected drugs among deaths with toxicology results were fentanyl (56%), morphine (46%), and gabapentin (32%), Table 6.
- The number of deaths involving amphetamine (+86%), methamphetamine (+75%), and fentanyl (+51%) largely increased from 2016 to 2017, <u>Table 6</u>.
- Mean blood concentration of fentanyl decreased from 2016 to 2017 despite the significant increase in deaths involving fentanyl, <u>Figure 3.</u>
- Opioids were the class of drugs most commonly identified in accidental drug overdose deaths (90%), whereas antidepressants were most commonly identified in drug overdose suicides (43%), <u>Table 12</u>.
- 7. Fentanyl was the most common drug detected in all demographic and socioeconomic groups, except among those 55 years and up and widowed decedents, where gabapentin was the most common detected drug (51%, 48% respectively), <u>Tables 13-16</u>.
- Black decedents had THC-COOH (33%) and cocaine (53%) detected significantly more often than white decedents (THC-COOH 20%, cocaine 17%), whereas gabapentin was more prevalent in white decedents (33%) over black decedents (19%), Table 15.
- Ethanol and cocaine detection increased with level of education completed; all other drugs were detected less as education level increased, <u>Table 16</u>.
- 10. The most common industries among decedents were construction (17%), other nonclassifiable or unspecified industry (10%), restaurants and other food services (9%), and healthcare (6%).

- Homemakers and those that did not work accounted for 11% and 8%, respectively, of nontraditional sectors, <u>Table 18</u>.
- 11. Large changes in death counts from 2016–2017 included increases in Kenton (+33), Jefferson (+29), Bullitt (+19), and Madison (+19) counties and a decrease in Harrison County (-13), Table 19.
- 12. The most common identifiable prescription and over-the-counter drugs found at the scene and/or autopsy were gabapentin (26%), hydrocodone (14%), and alprazolam (14%), Table 34.
- 13. The most common significant condition contributing to cause of death was heart-related conditions (16%), with just under half of the heart-related conditions being hypertension (7%), Figure 26.
- 14. Common medical conditions diagnosed among drug overdose decedents were unspecified substance use disorder (31%), opioid-related substance use disorder (25%), hypertension (13%), alcohol use disorder (10%), and depression (8%), Table 35.
- 15. Sixty-two percent of decedents had a reported substance use problem, 13% had a reported history of substance use relapse, 8% had a reported previous drug overdose, and 8% had reported ever receiving substance use treatment, <u>Table 37</u>.
- 16. Twelve percent of drug overdose decedents had a reported mental health history, while 2% of all drug overdose decedents had reported ever receiving treatment for their mental health, Table 37.
- 17. Fifteen percent of drug overdose decedents reported a major life change, crisis, or traumatic event occurring within the last month prior to the fatal event, and 10% of decedents were recently released from residential substance use treatment, from hospital/ER, or from jail/prison, Table 37.
- 18. Decedents with illicit opioids identified in toxicology at death had a large decrease in active legal opioid prescriptions from 180 days prior to death (39%) to the day of death (10%), Table 45.





DEFINITIONS

Drug overdose fatalities were identified from Kentucky death certificates as any deaths with the following underlying cause-of-death ICD-10 codes: 1) X40–X44 (accidental/unintentional drug poisoning); 2) X60–X64 (suicide by drug poisoning); 3) X85 (homicide by drug poisoning); and 4) Y10–Y14 (drug poisoning with undetermined intent).

DOFSS cases include all drug overdose fatalities that occurred in Kentucky, regardless of decedent state of residence, and all received Kentucky resident drug overdose fatalities that occurred out of state. Unless otherwise noted, both Kentucky residents and out-of-state residents who died of drug overdoses in Kentucky are included in DOFSS data counts.

Chi-Square Test: A statistical test of the dependence of two categorical variables, under the null hypothesis that the two variables are independent. The alternative hypothesis is that the variables are dependent.

Drug Paraphernalia: Denotes any equipment, product, or accessory used for making, using, or concealing drugs for recreational purposes. Examples of drug paraphernalia include: pipes, syringes, scales, razors, spoons, rolled bills, etc.

Fisher's Exact Test: An "exact" statistical test of the dependence of two categorical variables, under the null hypothesis that the two variables are independent. The alternative hypothesis is that the variables are dependent. Exact tests are used when the sample size is too small to meet the assumptions of traditional statistical tests, such as the chi-square test of independence.

Interquartile Range (IQR): A measure of statistical dispersion between 75th and 25th percentiles, IQR = Q_3 - Q_1 .

Percentile: The value that indicates the percentage of observations in a distribution that are below that value. For example, if the 95th percentile is 10, 95% of the distribution is below 10.

P-Value: The probability of finding the observed results under the assumption that the null hypothesis is true. P-values less than 0.05 are typically treated as significant, meaning the assumption that the null hypothesis is true can be rejected in favor of the alternative hypothesis.

Route of Administration: Witness reports or evidence found at the scene or autopsy that suggest how drugs were administered. Routes of administration are not mutually exclusive; a decedent may have more than one route of administration identified. Evidence identified is not unequivocal evidence that a specific route was use for the fatal event. Some types of evidence may be indicative of multiple routes of administration (i.e., filters are used for both injection and smoking).

Evidence of Injection—Witness reports or evidence found at the scene or autopsy that suggest drugs were injected by the decedent either intravenously, subcutaneously, or intramuscularly. Evidence of injection includes but is not limited to: track marks, fresh needle puncture wounds, needles, syringes, tourniquets, cookers, filters, and witness reports.

Evidence of Ingestion—Witness reports or evidence found at the scene or autopsy that suggest drugs were taken orally by the decedent. Evidence of ingestion includes but is not limited to: pills (marked or unmarked), pills found in stomach contents, pill bottles (empty or with pills), pill counts from scene, and witness reports. If pills or pill bottles are not closely associated with the scene or decedent, they will not be included as evidence of ingestion.





Evidence of Snorting—Witness reports or evidence found at the scene or autopsy that suggest drugs were snorted by the decedent. Evidence of snorting includes but is not limited to: crushed pills and powders, powder dust in or about nasal and oral cavities, straws, rolled up bills, razor blades or other cutting objects, or witness reports.

Evidence of Smoking—Witness reports or evidence found at the scene or autopsy that suggest drugs were smoked by the decedent. Evidence of smoking includes but is not limited to: pipes or stems, filters/screens, tin foil or cans, lighters, and witness reports.

Evidence of Transdermal Application—Witness reports or evidence found at the scene or autopsy that suggest drugs were absorbed through the decedent's skin. Evidence of transdermal application includes but is not limited to: transdermal patches, transdermal patch wrappings, leftover adhesive from patches on skin, and witness reports.

Therapeutic Range: A clinical reference range of blood plasma or serum concentration of a drug that is expected to achieve the desired therapeutic effects.

Unique Metabolite: A byproduct of the parent drug metabolizing and breaking down in the body that has been identified only in the parent drug. Non-unique metabolites are byproducts that are found in more than one metabolism process or that may act as both a parent drug and a metabolite of another drug.

For the purpose of this report, unique metabolites are classified and represented as the parent drug only. If a decedent has both the parent drug and the unique metabolite, the two separate drugs will be counted only once and labeled as the parent drug. This is true for all drugs with unique metabolites except for the unique metabolite of THC, due to the lengthy metabolism of THC-COOH. The list of the possible parent drugs and the included unique metabolites are listed below.

Alprazolam is identified by positive toxicology results for alprazolam and/or a-OH-alprazolam.

Amiodarone is identified by positive toxicology results for amiodarone and/or desethylamiodarone.

Aripiprazole is identified by positive toxicology results for aripiprazole and/or dehydroaripiprazole.

Buprenorphine is identified by positive toxicology results for buprenorphine and/or norbuprenorphine.

Carbamazepine is identified by positive toxicology results for carbamazepine and/or carbamazepine-10,11-epoxide.

Chlordiazepoxide is identified by positive toxicology results for chlordiazepoxide and/or demoxepam. **Clomipramine** is identified by positive toxicology results for clomipramine and/or norclomipramine (n-desmethylclomipramine).

Clonazepam is identified by positive toxicology results for clonazepam and/or 7-aminoclonazepam.

Clozapine is identified by positive toxicology results for clozapine and/or norclozapine.

Cocaine is identified by positive toxicology results for cocaine, cocaethylene, and/or benzoylecgonine.

Doxepin is identified by positive toxicology results for doxepin and/or nordoxepin.

Fentanyl is identified by positive toxicology results for fentanyl and/or norfentanyl.

Flunitrazepam is identified by positive toxicology results for flunitrazepam, 7-aminoflunitrazepam, and/or norflunitrazepam (n-desmethylflunitrazepam).

Fluoxetine is identified by positive toxicology results for fluoxetine and/or norfluoxetine.

Flurazepam is identified by positive toxicology results for flurazepam, desalkylflurazepam, and/or 2-hydroxyethylflurazepam.

Heroin is identified by positive toxicology results for diacetylmorphine and/or 6-monoacetylmorphine. **Ketamine** is identified by positive toxicology results for ketamine and/or norketamine.





Methadone is identified by positive toxicology results for methadone, EDDP, and/or EMDP.

Meperidine is identified by positive toxicology results for meperidine and/or normeperidine.

Oxcarbazepine is identified by positive toxicology results for 10-monohydroxy oxcarbazepine.

Papaverine is identified by positive toxicology results for papaverine and/or desmethylpapaverine.

Propoxyphene is identified by positive toxicology results for propoxyphene and/or norpropoxyphene.

Risperidone is identified by positive toxicology result for risperidone and/or 9-hydroxyrisperidone.

Sertraline is identified by positive toxicology results for sertraline and/or norsertraline.

Tramadol is identified by positive toxicology results for tramadol, nortramadol (n-desmethyltramadol), and/or desmetramadol (o-desmethyltramadol).

Triazolam is identified by positive toxicology results from triazolam and/or hydroxytriazolam.

Venlafaxine is identified by positive toxicology results for venlafaxine, norvenlafaxine (n-desmethylvenlafaxine), and/or desvenlafaxine (o-desmethylvenlafaxine).





2017 KENTUCKY DRUG OVERDOSE FATALITY SURVEILLANCE DATA

OVERALL DATA

Table 1. Overall Kentucky Drug Overdose Fatality Data, 2017

DOFSS drug overdose deaths, overall	1,561
Kentucky resident drug overdose fatalities occurring in Kentucky	1,456
Kentucky resident drug overdose fatalities occurring outside of Kentucky	8
Kentucky resident age-adjusted drug overdose fatality rate ¹	37.2
Out-of-state resident drug overdose deaths occurring in Kentucky	97
DOFSS drug overdose deaths with post-mortem toxicology results available	1,455
1	

¹Age-adjusted drug overdose fatality rate was calculated using Multiple Cause of Death 1999–2017 file on CDC WONDER Online Database.

Produced by the Kentucky Injury Prevention and Research Center, as bona fide agent for the Kentucky Department for Public Health. June 2020. Kentucky data sources: death certificates, Kentucky Office of Vital Statistics, Cabinet for Health and Family Services; post-mortem toxicology records and autopsy reports, Kentucky State Medical Examiner's Office, Justice and Public Safety Cabinet; Kentucky All Schedule Prescription Electronic Reporting, Office of Inspector General, Cabinet for Health and Family Services; and Kentucky coroner investigation reports, county coroners' offices. National data: Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999–2017 on CDC WONDER online database, released December 2018. Data are from the Multiple Cause of Death Files, 1999–2017, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperation Program. Data outputs draw from selected DOFSS data sources. Data are provisional and subject to change.





Table 2. Overall Demographic and Socioeconomic Factors Among Drug Overdose Decedents in Kentucky, 2017

	0 0			//	
Category		Drug Overdose	Kentucky	Kentucky	
	Drug Overdose	Decedent	Population	Population	
	Decedent Count	Percentage	Estimate ¹	Percentage	
Gender					
Male	957	61.3%	2,194,850	49.3%	
Female	604	38.7%	2,259,339	50.7%	
Age					
0–24 years	93	6.0%	1,435,236	32.2%	
25–34 years	402	25.8%	573,771	12.9%	
35–44 years	446	28.6%	555,670	12.5%	
45–54 years	391	25.0%	584,245	13.1%	
55+ years	229	14.7%	1,305,267	29.3%	
Race					
White	1446	92.6%	3,989,894	87.8%	
Black	100	6.4%	423,805	9.3%	
Other	15	1.0%	131,424	2.9%	
Marital Status ²					
Single	652	41.8%	1,040,408	28.8%	
Married ³	338	21.7%	1,864,065	51.6%	
Divorced	447	28.6%	473,241	13.1%	
Widowed	77	4.9%	234,814	6.5%	
Unknown Marital Status	47	3.0%	0	0.0%	
Education Level ⁴					
Less than High School	374	24.0%	461,216	13.4%	
High School /GED Equivalent	781	50.0%	1,155,278	33.6%	
Some College /Associates Degree	295	18.9%	1,062,272	30.9%	
Bachelor's Degree or Higher	85	5.4%	760,819	22.1%	
Unknown Education	26	1.7%	0	0.0%	

¹Kentucky population estimates for gender, age, race, marital status, and education level are from the U.S. Census Bureau's 2017 American Community Survey one-year estimates.





²Kentucky population marital status estimates are for ages 15+.

³"Married" includes, for both drug overdose decedent information and Kentucky population estimates, individuals who identify as separated but are not legally divorced.

⁴Kentucky population education level estimates are for ages 18+.

Table 3. Place of Injury Among Drug Overdose Decedents in Kentucky, 2017¹

Location of Injury	Count	Percentage
Home	987	63.2%
Other Specified Place, Not Classifiable, or Unspecified	500	32.0%
Residential Institution	30	1.9%
Street/Highway	26	1.7%
Trade and Service Area	7	0.4%
Industrial and Construction Area	<5	*
Farm	<5	*
School, Other Institutions, Administrative Area	<5	*
Sport and Recreational Area	<5	*

¹In accordance with state data release policy, counts less than five are suppressed. Any number associated with the suppressed count is labeled with an *.

Produced by the Kentucky Injury Prevention and Research Center, as bona fide agent for the Kentucky Department for Public Health. June 2020. Kentucky data sources: death certificates, Kentucky Office of Vital Statistics, Cabinet for Health and Family Services; post-mortem toxicology records and autopsy reports, Kentucky State Medical Examiner's Office, Justice and Public Safety Cabinet; Kentucky All Schedule Prescription Electronic Reporting, Office of Inspector General, Cabinet for Health and Family Services; and Kentucky coroner investigation reports, county coroners' offices. Data outputs draw from selected DOFSS data sources. Data are provisional and subject to change.

Table 4. Place of Death Among Drug Overdose Decedents in Kentucky, 2017¹

Location of Death	Count	Percentage
Residence	710	45.5%
Hospital, ER/Outpatient	326	20.9%
Other Specified Place, Not Classifiable, or Unspecified	315	20.2%
Hospital, Inpatient	197	12.6%
Hospital, Dead on Arrival	9	0.6%
Hospice	<5	*
Nursing Home/Long-Term Care Facility	<5	*

¹In accordance with state data release policy, counts less than five are suppressed. Any number associated with the suppressed count is labeled with an *.





POST-MORTEM TOXICOLOGY RESULTS

Table 5. Drug Classes Detected Among Drug Overdose Decedents in Kentucky, 2017¹

			Percent Change
Drug Class ²⁻⁴	2017 Count	2017 Percentage ⁵	From 2016-2017 ⁶
Opioids ⁷	1,273	87.49%	5.6%
Benzodiazepines	619	42.54%	-6.6%
Amphetamines	484	33.26%	65.2%
Anticonvulsants	475	32.65%	-1.5%
Cannabinoids	319	21.92%	-15.6%
Cocaine	281	19.31%	21.1%
Alcohol	244	16.77%	-10.6%
Stimulants	57	3.92%	-10.9%
Antidepressants	49	3.37%	6.5%
Non-Opioid Analgesics	39	2.68%	-4.9%
Cardiovascular	23	1.58%	76.9%
Antihistamines	21	1.44%	-12.5%
Antipsychotics	12	0.82%	-20.0%
Sedatives/Hypnotics	7	0.48%	-36.4%
Anesthetics	5	0.34%	-
Barbiturates	<5	*	*
Narcotics	<5	*	*
Miscellaneous	<5	*	*
Antibiotics	0	0.00%	*
Bath Salts	0	0.00%	-
Endocrine	0	0.00%	-
Gastrointestinal Agents	0	0.00%	-
Neurological Agents	0	0.00%	*

¹In accordance with state data release policy, counts less than five are suppressed. Any number directly associated with the suppressed count is labeled with an *. A count greater than five or an associated number may not be reported if that value would disclose a suppressed value; these are labeled with a -.





²Drug testing of blood, urine, and/or vitreous fluids.

³Drug classes are not mutually exclusive; decedents may have multiple drug classes detected.

⁴Multiple drugs within the same drug class are counted as one drug class incident per decedent.

⁵Percentage is based on total number of DOFSS drug overdose fatalities with toxicology results available, n=1,455.

⁶Percent Change represents the change in individual drug frequency from 2016 to 2017.

^{7"}Opioids" includes all opium-like substances (including natural opiates, semi-synthetic opioids, and synthetic opioids).

Table 6. Most Frequent Drugs Detected Among Drug Overdose Decedents in Kentucky, 2017¹

Drug ^{2–4}	2017 Count	2017 Percentage ⁵	Percent Change From 2016–2017 ⁶
Fentanyl ⁴	819	56.3%	50.6%
Morphine ⁷	672	46.2%	0.7%
Gabapentin	466	32.0%	-2.9%
Methamphetamine	440	30.2%	74.6%
Amphetamine	369	25.4%	86.4%
Alprazolam ⁴	347	23.8%	-7.2%
Heroin ⁴	344	23.6%	-5.2%
THC-COOH ⁴	304	20.9%	-16.9%
Cocaine ⁴	282	19.4%	20.5%
Codeine	271	18.6%	-10.9%
Ethanol	239	16.4%	-11.8%
Clonazepam ⁴	233	16.0%	-3.3%
Oxycodone	216	14.8%	-14.6%
Hydromorphone	201	13.8%	-14.5%
Hydrocodone	187	12.9%	-13.4%
THC ⁴	166	11.4%	-2.4%
Oxymorphone	156	10.7%	-23.2%
Oxazepam	128	8.8%	-12.9%
Nordiazepam	116	8.0%	-22.1%
Buprenorphine ⁴	106	7.3%	3.9%
Temazepam	101	6.9%	-16.5%
Diazepam	65	4.5%	-40.4%
Methadone ⁴	60	4.1%	-11.8%
Tramadol ⁴	48	3.3%	2.1%
Cotinine	48	3.3%	-2.0%
Nicotine	39	2.7%	-7.1%
Lorazepam	34	2.3%	21.4%
Caffeine	32	2.2%	-13.5%
Citalopram	15	1.0%	87.5%
Diphenhydramine	15	1.0%	-11.8%
Carfentanil	14	1.0%	55.6%
Pseudoephedrine	14	1.0%	-30.0%
Acetaminophen	13	0.9%	*
Bupropion	12	0.8%	50.0%





Table 6. Most Frequent Drugs Detected Among Drug Overdose Decedents in Kentucky, 2017¹—continued

Drug ²⁻⁴	2017 Count	2017 Percentage ⁵	Percent Change From 2016–2017 ⁶
Naloxone	12	0.8%	0.0%
Furanylfentanyl	9	0.6%	*
Nortriptyline	9	0.6%	28.6%
Propanolol	8	0.5%	*
MDMA	8	0.5%	*
Fluoxetine ⁴	7	0.5%	16.7%
Venlafaxine ⁴	7	0.5%	16.7%
Metoprolol	7	0.5%	*
Amitriptyline	7	0.5%	0.0%
Cyclobenzaprine	7	0.5%	-22.2%
Quetiapine	7	0.5%	-36.4%
Chlordiazepoxide ⁴	6	0.4%	-14.3%
Zolpidem	5	0.3%	*
Trazodone	5	0.3%	-44.4%
Meprobamate	5	0.3%	-54.5%

¹In accordance with state data release policy, counts less than five are suppressed. Any number directly associated with the suppressed count is labeled with an *. A count greater than five or an associated number may not be reported if that value would disclose a suppressed value; these are labeled with a -.





²Drug testing of blood, urine, and/or vitreous fluids.

³Drugs are not mutually exclusive; decedents may have more than one drug detected.

⁴Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

⁵Percentage is based on total number of DOFSS drug overdose fatalities with toxicology results available, n=1,455.

⁶Percent Change represents the change in individual drug frequency from 2016 to 2017.




Figure 1. Total Number of Drugs Detected Per Drug Overdose Decedent in Kentucky, 2017^{1–4}

²Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

³Percentage is based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results, n=1,453.

⁴An unknown number of drugs is due to a decedent having a toxicology screening performed with drug class information only.

Produced by the Kentucky Injury Prevention and Research Center, as bona fide agent for the Kentucky Department for Public Health. June 2020. Kentucky data sources: death certificates, Kentucky Office of Vital Statistics, Cabinet for Health and Family Services; post-mortem toxicology records and autopsy reports, Kentucky State Medical Examiner's Office, Justice and Public Safety Cabinet; Kentucky All Schedule Prescription Electronic Reporting, Office of Inspector General, Cabinet for Health and Family Services; and Kentucky coroner investigation reports, county coroners' offices. Data outputs draw from selected DOFSS data sources. Data are provisional and subject to change.

Table 7. Percentile of Total Number of Drugs Detected Per Drug Overdose Decedents in Kentucky, 2017^{1–2}

5 th	10 th	25 th	50 th	75 th	90 th	95 th
percentile	percentile	percentile	percentile	percentile	percentile	percentile
1 drug per	2 drugs per	3 drugs per	4 drugs per	6 drugs per	8 drugs per	10 drugs per
decedent	decedent	decedent	decedent	decedent	decedent	decedent

¹Drug testing of blood, urine, and/or vitreous fluids.

²Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.





¹Drug testing of blood, urine, and/or vitreous fluids.

Table 8. Most Frequent Drugs Detected Among Kentucky Drug Overdose Decedents with Less Than Four Total Drugs in Post-Mortem Toxicology, 2017

Count	Percentage⁴
269	48.82%
129	23.41%
119	21.60%
95	17.24%
76	13.79%
75	13.61%
58	10.53%
56	10.16%
53	9.62%
43	7.80%
31	5.63%
29	5.26%
22	3.99%
21	3.81%
16	2.90%
16	2.90%
12	2.18%
9	1.63%
9	1.63%
8	1.45%
7	1.27%
6	1.09%
6	1.09%
	269 129 119 95 76 75 58 58 56 53 43 31 29 22 21 16 16 16 19 9 9

¹Drug testing of blood, urine, and/or vitreous fluids.






²Drugs are not mutually exclusive; decedents may have more than one drug detected.


³Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

⁴Percentage is based on total number of DOFSS drug overdose fatalities with less than four drugs identified in toxicology results. n=551.

⁵Morphine may represent pure morphine and/or a metabolite of heroin.

Figure 2. Most Frequent Drugs Found in Combination with Commonly Detected Drugs Among Drug Overdose














Figure 2. Most Frequent Drugs Found in Combination with Commonly Detected Drugs Among Drug Overdose Decedents in Kentucky, 2017^{1-3} —continued














Figure 2. Most Frequent Drugs Found in Combination with Commonly Detected Drugs Among Drug Overdose Decedents in Kentucky, 2017^{1-3} —continued














Figure 2. Most Frequent Drugs Found in Combination with Commonly Detected Drugs Among Drug Overdose Decedents in Kentucky, 2017^{1-3} —continued













Figure 2. Most Frequent Drugs Found in Combination with Commonly Detected Drugs Among Drug Overdose Decedents in Kentucky, 2017^{1-3} —continued



¹Drug testing of blood, urine, and/or vitreous fluids.

⁴Morphine may represent pure morphine and/or a metabolite of heroin.





²Drugs are not mutually exclusive; decedents may have more than one drug detected.

³Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

Table 9. Most Common Two-Drug Combinations Detected Among Drug Overdose Decedents in Kentucky, 2017

Two-Drug Combination ^{1–4}	Count	Percentage⁵
Fentanyl and Morphine ⁶	510	35.1%
Amphetamine and Methamphetamine	347	23.8%
Heroin and Morphine ⁶	342	23.5%
Codeine and Morphine ⁶	264	18.1%
Fentanyl and Heroin	259	17.8%
Fentanyl and Methamphetamine	256	17.6%
Methamphetamine and Morphine ⁶	235	16.2%
Amphetamine and Fentanyl	219	15.1%
Fentanyl and Gabapentin	217	14.9%
Codeine and Heroin	213	14.6%

¹Drug testing of blood, urine, and/or vitreous fluids.





²Drug combinations are not mutually exclusive; decedents may have had more than one drug combination detected.

³Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

⁴Drug combinations may represent a parent drug and a nonspecific metabolite or adulterant.

⁵Percentage is based on total number of DOFSS drug overdose fatalities with toxicology results available, n=1,455.

⁶Morphine may represent pure morphine and/or a metabolite of heroin.

Table 10. Most Common Three-Drug Combinations Detected Among Drug Overdose Decedents in Kentucky, 2017

Three-Drug Combination ¹⁻⁴	Count	Percentage ⁵
Fentanyl, Heroin, and Morphine ⁶	257	17.7%
Codeine, Heroin, and Morphine ⁶	213	14.6%
Amphetamine, Fentanyl, and Methamphetamine	205	14.1%
Amphetamine, Methamphetamine, and Morphine ⁶	199	13.7%
Codeine, Fentanyl, and Morphine ⁶	191	13.1%
Fentanyl, Methamphetamine, and Morphine ⁶	185	12.7%
Amphetamine, Fentanyl, and Morphine ⁶	164	11.3%
Codeine, Fentanyl, and Heroin	158	10.9%
Fentanyl, Gabapentin, and Morphine ⁶	141	9.7%
Heroin, Methamphetamine, and Morphine ⁶	129	8.9%

¹Drug testing of blood, urine, and/or vitreous fluids.





²Drug combinations are not mutually exclusive; decedents may have had more than one drug combination detected.

³Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

⁴Drug combinations may represent a parent drug and a nonspecific metabolite or adulterant.

⁵Percentage is based on total number of DOFSS drug overdose fatalities with toxicology results available, n=1,455.

⁶Morphine may represent pure morphine and/or a metabolite of heroin.

Table 11. Most Common Four-Drug Combinations Detected Among Drug Overdose Decedents in Kentucky, 2017

Four-Drug Combination ^{1–4}	Count	Percentage⁵
Codeine, Fentanyl, Heroin, and Morphine ⁶	158	10.9%
Amphetamine, Fentanyl, Methamphetamine, and Morphine ⁶	156	10.7%
Amphetamine, Heroin, Methamphetamine, and Morphine ⁶	109	7.5%
Fentanyl, Heroin, Methamphetamine, and Morphine ⁶	101	6.9%
Amphetamine, Codeine, Methamphetamine, and Morphine ⁶	92	6.3%
Codeine, Heroin, Methamphetamine, and Morphine ⁶	91	6.3%
Amphetamine, Fentanyl, Heroin, and Morphine ⁶	88	6.0%
Codeine, Fentanyl, Methamphetamine, and Morphine ⁶	84	5.8%
Amphetamine, Fentanyl, Heroin, and Methamphetamine	84	5.8%
Codeine, Heroin, Hydromorphone, and Morphine ⁶	79	5.4%

¹Drug testing of blood, urine, and/or vitreous fluids.





²Drug combinations are not mutually exclusive; decedents may have had more than one drug combination detected.

³Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

⁴Drug combinations may represent a parent drug and a nonspecific metabolite or adulterant.

⁵Percentage is based on total number of DOFSS drug overdose fatalities with toxicology results available, n=1,455.

⁶Morphine may represent pure morphine and/or a metabolite of heroin.

Figure 3. Median Blood Concentration, Interquartile Range, and Therapeutic Range of Top Therapeutic Drugs Identified Among Drug Overdose Decedents in Kentucky, 2017^{1-3}








Figure 3. Median Blood Concentration, Interquartile Range, and Therapeutic Range of Top Therapeutic Drugs Identified Among Drug Overdose Decedents in Kentucky, 2017^{1–3} –continued









Figure 3. Median Blood Concentration, Interquartile Range, and Therapeutic Range of Top Therapeutic Drugs Identified Among Drug Overdose Decedents in Kentucky, 2017^{1–3} –continued



¹Drug testing of blood only, due to lack of correlation of urine and vitreous concentrations with therapeutic range.





²Drugs are not mutually exclusive; decedents may have more than one drug detected.

³The Interquartile Range is the statistical dispersion between the 75th and 25th percentiles of the blood concentration of all drug overdose decedents with the specified drug identified via toxicological analysis.

⁴A therapeutic range for buprenorphine has not been clearly established (https://www.ata-journal.org/articles/ata/pdf/2004/04/ata20044p275.pdf).

Table 12. Drug Classes Identified Among Drug Overdose Decedents in Kentucky by Suicide and Accidental Manners of Death, 2017^{1–3}

	Suicide, n=51	Accidental, n=1,355	Chi-Square p-	Fisher's Exact
Drug Class ^{4–5}	(%)	(%)	value ⁶	p-value ⁷
Opioids ⁸	21 (41.2%)	1,218 (89.9%)	<.01	nc
Benzodiazepines	19 (37.3%)	579 (42.7%)	0.44	nc
Amphetamines	12 (23.5%)	458 (33.8%)	0.13	nc
Anticonvulsants	15 (29.4%)	435 (32.1%)	0.69	nc
Cannabinoids	<5 (*)	309 (22.8%)	<.01	nc
Cocaine	<5 (*)	273 (20.1%)	0.03	nc
Alcohol	15 (29.4%)	223 (16.5%)	0.02	nc
Stimulants	19 (37.3%)	32 (2.4%)	<.01	<.01
Antidepressants	22 (43.1%)	24 (1.8%)	<.01	<.01
Non-Opioid Analgesics	12 (23.5%)	23 (1.7%)	<.01	<.01
Cardiovascular Agents	12 (23.5%)	11 (0.8%)	<.01	<.01
Antihistamines	11 (21.6%)	7 (0.5%)	<.01	<.01
Antipsychotics	<5 (*)	6 (0.4%)	<.01	<.01
Barbiturates	<5 (*)	<5 (*)	<.01	<.01
Anesthetics	<5 (*)	<5 (*)	<.01	<.01
Sedatives/Hypnotics	<5 (*)	<5 (*)	<.01	<.01
Narcotics	<5 (*)	0	<.01	0.04
Miscellaneous	0	<5 (*)	0.74	1.00

¹Undetermined, homicide, and natural manners of death were excluded from this analysis.





²Counts are based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results for each manner group.

³In accordance with state data release policy, counts less than five are suppressed. Any number associated with the suppressed count is labeled with an *.

⁴Drug testing of blood, urine, and/or vitreous fluids.

⁵Drugs are not mutually exclusive; decedents may have more than one drug detected.

⁶*p*-value from chi-square test of independence, which tests if a statistical association exists between manner of death and a positive finding for the specified drug in post-mortem toxicology.

 $^{^{7}}p$ -value from Fisher-exact test included for instances where chi-square assumptions may be violated. Where no violation, Fisher-exact test not calculated and labeled with nc.

⁸"Opioids" includes all opium-like substances (including natural opiates, semi-synthetic opioids, and synthetic opioids).

DRUG OVERDOSE FATALITY DEMOGRAPHICS

Table 13. Most Frequent Drugs Identified Among Drug Overdose Decedents in Kentucky by Gender, 2017¹

	Female (%)	Male (%)	
Drug ²⁴	N=564	N=889	p-value⁵
Fentanyl ⁴	270 (47.9%)	549 (61.8%)	<.01
Morphine ⁶	215 (38.1%)	457 (51.4%)	<.01
Gabapentin	229 (40.6%)	237 (26.7%)	<.01
Methamphetamine	149 (26.4%)	291 (32.7%)	0.01
Amphetamine	113 (20.0%)	256 (28.8%)	<.01
Alprazolam ⁴	146 (25.9%)	192 (21.6%)	0.06
Heroin⁴	92 (16.3%)	252 (28.3%)	<.01
THC-COOH⁴	102 (18.1%)	202 (22.7%)	0.03
Cocaine ⁴	103 (18.3%)	180 (20.2%)	0.35
Codeine	86 (15.2%)	185 (20.8%)	<.01
Ethanol	76 (13.5%)	162 (18.2%)	0.02
Clonazepam ⁴	108 (19.1%)	125 (14.1%)	0.01
Oxycodone	87 (15.4%)	129 (14.5%)	0.63

¹Counts are based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results for each gender.





²Drug testing of blood, urine, and/or vitreous fluids.

³Drugs are not mutually exclusive; decedents may have more than one drug detected.

⁴Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

⁵*p*-value from chi-square test of independence, which tests if a statistical association exists between gender and a positive finding for the specified drug in post-mortem toxicology.

⁶Morphine may represent pure morphine and/or a metabolite of heroin.

Table 14. Most Frequent Drugs Identified Among Drug Overdose Decedents in Kentucky by Age Group, 2017¹

	0-24 years (%)	25-34 years (%)	35-44 years (%)	45-54 years	55+ years (%)
Drug ²⁻⁴	N=87	N=382	N=422	(%) N=359	N=203
Fentanyl ⁴	59 (67.8%)	260 (68.1%)	261 (61.8%)	162 (45.1%)	77 (37.9%)
Morphine⁵	51 (58.6%)	214 (56.0%)	210 (49.8%)	127 (35.4%)	70 (34.5%)
Gabapentin	8 (9.2%)	87 (22.8%)	124 (29.4%)	143 (39.8%)	104 (51.2%)
Methamphetamine	21 (24.1%)	142 (37.2%)	139 (32.9%)	100 (27.9%)	38 (18.7%)
Amphetamine	20 (23.0%)	121 (31.7%)	117 (27.7%)	83 (23.1%)	28 (13.8%)
Alprazolam ⁴	14 (16.1%)	91 (23.8%)	87 (20.6%)	94 (26.2%)	52 (25.6%)
Heroin⁴	27 (31.0%)	119 (31.2%)	105 (24.9%)	60 (16.7%)	33 (16.3%)
THC-COOH⁴	22 (25.3%)	97 (25.4%)	100 (23.7%)	64 (17.8%)	21 (10.3%)
Cocaine ⁴	13 (14.9%)	80 (20.9%)	89 (21.1%)	62 (17.3%)	39 (19.2%)
Codeine	23 (26.4%)	95 (24.9%)	81 (19.2%)	43 (12.0%)	29 (14.3%)
Ethanol	9 (10.3%)	45 (11.8%)	80 (19.0%)	67 (18.7%)	37 (18.2%)
Clonazepam⁴	9 (10.3%)	55 (14.4%)	67 (15.9%)	65 (18.1%)	37 (18.2%)
Oxycodone	7 (8.0%)	31 (8.1%)	52 (12.3%)	81 (22.6%)	45 (22.2%)

¹Counts are based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results for that age group.

⁵Morphine may represent pure morphine and/or a metabolite of heroin.





²Drug testing of blood, urine, and/or vitreous fluids.

³Drugs are not mutually exclusive; decedents may have more than one drug detected.

⁴Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

Table 15. Most Frequent Drugs Identified Among Drug Overdose Decedents in Kentucky by Race, 2017¹⁻²

	Black (%)	White (%)	
Drug ^{3–5}	N=95	N=1344	p-value ⁶
Fentanyl ⁵	60 (63.2%)	749 (55.7%)	0.16
Morphine ⁷	40 (42.1%)	626 (46.6%)	0.40
Gabapentin	18 (18.9%)	446 (33.2%)	<.01
Methamphetamine	21 (22.1%)	415 (30.9%)	0.07
Amphetamine	16 (16.8%)	349 (26.0%)	0.05
Alprazolam ⁵	17 (17.9%)	318 (23.7%)	0.20
Heroin ⁵	19 (20.0%)	320 (23.8%)	0.40
THC-COOH⁵	31 (32.6%)	270 (20.1%)	<.01
Cocaine ⁵	50 (52.6%)	229 (17.0%)	<.01
Codeine	18 (18.9%)	249 (18.5%)	0.92
Ethanol	20 (21.1%)	212 (15.8%)	0.18
Clonazepam⁵	7 (7.4%)	225 (16.7%)	0.02
Oxycodone	6 (6.3%)	209 (15.6%)	0.01

¹Asian/Pacific Islander, Indian, Other, and Unknown Race were excluded from these analyses due to low counts.

⁶*p*-value from chi-square test of independence, which tests if a statistical association exists between race and a positive finding for the specified drug in post-mortem toxicology.





²Counts are based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results for that race.

³Drug testing of blood, urine, and/or vitreous fluids.

⁴Drugs are not mutually exclusive; decedents may have more than one drug detected.

⁵Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

⁷Morphine may represent pure morphine and/or a metabolite of heroin.

DRUG OVERDOSE FATALITY SOCIOECONOMIC FACTORS

Table 16. Most Frequent Drugs Identified Among Drug Overdose Decedents in Kentucky by Education Level, 2017^{1-2}

Drug ³⁻⁵	Less than High School (%) N=337	High School /GED Equivalent (%) N=732	Some College/Associat es Degree (%) N=282	Bachelor's Degree or Higher (%) N=79	Unknown Education (%) N=23
Fentanyl ⁵	182 (54.0%)	422 (57.7%)	170 (60.3%)	32 (40.5%)	13 (56.5%)
Morphine ⁶	162 (48.1%)	346 (47.3%)	129 (45.7%)	25 (31.6%)	10 (43.5%)
Gabapentin	144 (42.7%)	213 (29.1%)	70 (24.8%)	26 (32.9%)	13 (56.5%)
Methamphetamine	116 (34.4%)	238 (32.5%)	65 (23.0%)	14 (17.7%)	7 (30.4%)
Amphetamine	90 (26.7%)	205 (28.0%)	56 (19.9%)	13 (16.5%)	5 (21.7%)
Alprazolam ⁵	85 (25.2%)	162 (22.1%)	70 (24.8%)	15 (19.0%)	6 (26.1%)
Heroin⁵	79 (23.4%)	180 (24.6%)	66 (23.4%)	14 (17.7%)	5 (21.7%)
THC-COOH ⁵	84 (24.9%)	158 (21.6%)	49 (17.4%)	8 (10.1%)	5 (21.7%)
Cocaine ⁵	61 (18.1%)	135 (18.4%)	63 (22.3%)	19 (24.1%)	5 (21.7%)
Codeine	65 (19.3%)	140 (19.1%)	52 (18.4%)	10 (12.7%)	<5 (*)
Ethanol	50 (14.8%)	114 (15.6%)	50 (17.7%)	19 (24.1%)	5 (21.7%)
Clonazepam ⁵	55 (16.3%)	123 (16.8%)	42 (14.9%)	10 (12.7%)	<5 (*)
Oxycodone	58 (17.2%)	101 (13.8%)	43 (15.2%)	12 (15.2%)	<5 (*)

¹Counts are based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results for that education group.

⁶Morphine may represent pure morphine and/or a metabolite of heroin.





²In accordance with state data release policy, counts less than five are suppressed. Any number associated with the suppressed count is labeled with an *.

³Drug testing of blood, urine, and/or vitreous fluids.

⁴Drugs are not mutually exclusive; decedents may have more than one drug detected.

⁵Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

Table 17. Most Frequent Drugs Identified Among Drug Overdose Decedents in Kentucky by Marital Status, 2017^{1–2}

	Single (%)	Married (%)	Divorced (%)	Widowed (%)	Unknown (%)
Drug ³⁻⁵	N=617	N=317	N=411	N=66	N=42
Fentanyl ⁵	409 (66.3%)	136 (42.9%)	221 (53.8%)	28 (42.4%)	25 (59.5%)
Morphine ⁶	326 (52.8%)	122 (38.5%)	179 (43.6%)	23 (34.8%)	22 (52.4%)
Gabapentin	134 (21.7%)	122 (38.5%)	159 (38.7%)	32 (48.5%)	19 (45.2%)
Methamphetamine	193 (31.3%)	92 (29.0%)	122 (29.7%)	13 (19.7%)	20 (47.6%)
Amphetamine	168 (27.2%)	72 (22.7%)	104 (25.3%)	9 (13.6%)	16 (38.1%)
Alprazolam ⁵	134 (21.7%)	77 (24.3%)	99 (24.1%)	14 (21.2%)	14 (33.3%)
Heroin⁵	181 (29.3%)	60 (18.9%)	81 (19.7%)	8 (12.1%)	14 (33.3%)
THC-COOH⁵	138 (22.4%)	65 (20.5%)	89 (21.7%)	<5 (*)	9 (21.4%)
Cocaine ⁵	130 (21.1%)	43 (13.6%)	85 (20.7%)	16 (24.2%)	9 (21.4%)
Codeine	136 (22.0%)	45 (14.2%)	72 (17.5%)	6 (9.1%)	12 (28.6%)
Ethanol	96 (15.6%)	55 (17.4%)	69 (16.8%)	13 (19.7%)	5 (11.9%)
Clonazepam⁵	88 (14.3%)	53 (16.7%)	67 (16.3%)	17 (25.8%)	8 (19.0%)
Oxycodone	68 (11.0%)	62 (19.6%)	68 (16.5%)	16 (24.2%)	<5 (*)

¹Counts are based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results for that marital status.

⁶Morphine may represent pure morphine and/or a metabolite of heroin.





²In accordance with state data release policy, counts less than five are suppressed. Any number associated with the suppressed count is labeled with an *.

³Drug testing of blood, urine, and/or vitreous fluids.

⁴Drugs are not mutually exclusive; decedents may have more than one drug detected.

⁵Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

Table 18. Most Frequent Industries Identified Among Drug Overdose Decedents in Kentucky, 2017

Industry ¹	Count	Percentage ²
Construction	267	17.1%
Homemaker	177	11.3%
Other industry, not classifiable, or unspecified	162	10.4%
Restaurants and other food services	136	8.7%
Did not work	124	7.9%
Healthcare facilities	89	5.7%
Not specified manufacturing industries	87	5.6%
Landscaping services	36	2.3%
Not specified retail trade	33	2.1%
Truck transportation	26	1.7%
Automotive repair and maintenance	25	1.6%
Student	20	1.3%
Crop production	15	1.0%
Warehousing and storage	15	1.0%
Coal mining	14	0.9%
Grocery stores	13	0.8%
Motor vehicles and motor vehicle equipment manufacturing	12	0.8%
Justice, public order, and safety activities	11	0.7%
Traveler accommodation	11	0.7%

¹Industry was determined using death certificate data and the NIOSH NIOCCS 3 auto-coder program.





²Percentage is based on total number of DOFSS drug overdose fatalities, n=1,561.

KENTUCKY RESIDENT DRUG OVERDOSE FATALITY COUNTS AND RATES

Table 19. Kentucky Resident Drug Overdose Fatality Counts and Rates by County, 2016–2017^{1–2}

19. Refitucky Nesidelit Drug OV		2016 Rate	,,,	2017 Rate	
		(per 100,000		(per 100,000	
County	2016 Count	population)	2017 Count	population)	Alert ³
Adair	<5	*	<5	*	
Allen	5	*	<5	*	
Anderson	9	*	11	48.79	
Ballard	<5	*	<5	*	
Barren	5	*	11	25.11	
Bath	<5	*	<5	*	
Bell	10	36.9	8	*	
Boone	42	32.7	44	33.66	
Bourbon	<5	*	7	*	
Boyd	25	51.9	31	64.61	
Boyle	16	53.3	8	*	
Bracken	<5	*	<5	*	
Breathitt	6	*	<5	*	
Breckinridge	<5	*	<5	*	
Bullitt	19	24.0	38	47.35	! (个)
Butler	<5	*	<5	*	
Caldwell	<5	*	<5	*	
Calloway	5	*	<5	*	
Campbell	67	72.7	60	64.87	
Carlisle	0	0.0	0	0	
Carroll	<5	*	<5	*	
Carter	9	*	14	51.58	
Casey	5	*	6	*	
Christian	<5	*	7	*	
Clark	9	*	17	47.16	
Clay	5	*	<5	*	
Clinton	<5	*	<5	*	
Crittenden	<5	*	<5	*	
Cumberland	<5	*	<5	*	
Daviess	13	13.0	11	10.96	
Edmonson	<5	*	<5	*	
Elliott	<5	*	<5	*	
Estill	9	*	10	70.04	
Fayette	115	36.1	125	38.82	! (个)





Table 19. Kentucky Resident Drug Overdose Fatality Counts and Rates by County, 2016–2017^{1–2} –continued

	2016 Rate 2017 Rate				
		(per 100,000		(per 100,000	
County	2016 Count	population)	2017 Count	population)	Alert ³
Fleming	<5	*	<5	*	
Floyd	16	43.1	12	33.08	
Franklin	15	29.7	25	49.52	! (个)
Fulton	0	0.0	<5	*	
Gallatin	6	*	8	*	
Garrard	8	*	5	*	
Grant	15	60.2	8	*	
Graves	5	*	<5	*	
Grayson	12	45.8	11	41.73	
Green	<5	*	<5	*	
Greenup	7	*	13	36.6	
Hancock	<5	*	<5	*	
Hardin	26	24.2	17	15.73	
Harlan	8	*	9	*	
Harrison	23	123.4	10	53.25	! (↓)
Hart	<5	*	<5	*	
Henderson	5	*	8	*	
Henry	<5	*	<5	*	
Hickman	<5	*	0	0	
Hopkins	9	*	13	28.54	
Jackson	<5	*	<5	*	
Jefferson	321	41.9	350	45.39	! (个)
Jessamine	16	30.6	30	56.21	! (个)
Johnson	<5	*	<5	*	
Kenton	82	49.7	115	69.53	! (个)
Knott	<5	*	<5	*	
Knox	10	31.6	13	41.63	
Larue	0	0.0	<5	*	
Laurel	9	*	12	19.94	
Lawrence	5	*	<5	*	· · ·
Lee	<5	*	<5	*	
Leslie	6	*	<5	*	
Letcher	<5	*	7	*	
Lewis	0	0.0	<5	*	
Lincoln	9	*	7	*	
Livingston	<5	*	<5	*	





Table 19. Kentucky Resident Drug Overdose Fatality Counts and Rates by County, 2016–2017^{1–2} –continued

		2016 Rate		2017 Rate	
		(per 100,000		(per 100,000	
County	2016 Count	population)	2017 Count	population)	Alert ³
Logan	5	*	0	0	
Lyon	0	0.0	<5	*	
Madison	25	27.9	44	48.23	!(个)
Magoffin	<5	*	<5	*	
Marion	<5	*	5	*	
Marshall	10	31.9	<5	*	
Martin	<5	*	<5	*	
Mason	11	64.0	10	58.23	
McCracken	12	18.4	8	*	
McCreary	<5	*	<5	*	
McLean	<5	*	0	0	
Meade	10	35.6	9	*	
Menifee	<5	*	<5	*	
Mercer	10	46.6	<5	*	
Metcalfe	<5	*	<5	*	
Monroe	<5	*	<5	*	
Montgomery	10	36.0	15	53.71	
Morgan	<5	*	<5	*	
Muhlenberg	<5	*	6	*	
Nelson	11	24.1	19	41.63	
Nicholas	<5	*	0	0	
Ohio	<5	*	<5	*	
Oldham	11	16.8	7	*	
Owen	7	*	<5	*	
Owsley	<5	*	<5	*	
Pendleton	7	*	8	*	
Perry	9	*	7	*	
Pike	16	26.4	11	18.68	
Powell	6	*	<5	*	
Pulaski	13	20.3	13	20.17	
Robertson	<5	*	<5	*	
Rockcastle	6	*	6	*	
Rowan	7	*	6	*	
Russell	6	*	<5	*	
Scott	20	37.1	13	23.69	
Shelby	15	32.3	11	23.2	





Table 19. Kentucky Resident Drug Overdose Fatality Counts and Rates by County, 2016–2017^{1–2} –continued

		2016 Rate		2017 Rate	
County	2016 Count	(per 100,000 population)	2017 Count	(per 100,000 population)	Alert ³
Simpson	<5	*	<5	*	
Spencer	5	*	6	*	
Taylor	5	*	8	*	
Todd	<5	*	0	0	
Trigg	<5	*	<5	*	
Trimble	<5	*	<5	*	
Union	<5	*	<5	*	
Warren	16	12.8	13	10.09	
Washington	<5	*	<5	*	
Wayne	<5	*	5	*	
Webster	<5	*	<5	*	
Whitley	7	*	11	30.37	
Wolfe	0	0.0	0	0	
Woodford	<5	*	5	*	

¹In accordance with state data release policy, counts less than five and rates based on counts less than 10 are suppressed. Any number associated with the suppressed count or rate is labeled with an *.





²Rates based on counts less than 20 are unstable and should be interpreted with caution.

³Alerts indicate an increase or decrease in count from year to year greater than or equal to 10.

Overdose Rate

0.0

0.1 - 28.2

28.3 - 48.2


48.3 - 123.4

Suppressed

Unstable

Figure 4. Kentucky Resident Drug Overdose Fatality Rates per 100,000 Population by County, 2016¹⁻²

Figure 5. Kentucky Resident Drug Overdose Fatality Rates per 100,000 Population by County, 2017^{1–2}



¹In accordance with state data release policy, rates based on counts less than 10 are suppressed.





²Rates based on counts less than 20 are unstable and should be interpreted with caution.

Table 20. Kentucky Resident Drug Overdose Fatality Counts and Rates by Kentucky Area Development District (ADD), 2016–2017¹

		2016 Rate (per 100,000		2017 Rate (per 100,000	
ADD District	2016 Count	population)	2017 Count	population)	Alert ²
Barren River	45	15.0	39	12.9	
Big Sandy	41	28.2	33	23.3	
Bluegrass	298	36.6	322	39.1	
Buffalo Trace	18	32.3	21	37.9	
Cumberland Valley	56	24.0	64	27.6	
FIVCO	49	36.4	62	46.3	
Gateway	25	29.7	29	34.3	
Green River	35	16.1	29	13.4	
KIPDA	375	37.5	417	41.4	! (个)
Kentucky River	30	27.9	25	23.6	
Lake Cumberland	40	19.2	49	23.4	
Lincoln Trail	66	24.2	67	24.4	
Northern Kentucky	229	50.3	251	54.8	
Pennyrile	24	11.2	36	16.9	
Purchase	36	18.4	20	10.2	

¹Rates based on counts less than 20 are unstable and should be interpreted with caution.





²Alerts indicate an increase or decrease in count from year to year greater than or equal to 30.

Table 21. Kentucky Resident Drug Overdose Fatality Counts Involving Scheduled Controlled Substances and Unscheduled Drugs by Kentucky Area Development District (ADD), 2017^{1–4}

ADD District	Schedule I	Schedule II	Schedule III	Schedule IV	Unscheduled
Barren River	13	28	<5	17	22
Big Sandy	11	28	10	26	27
Bluegrass	130	299	20	142	144
Buffalo Trace	7	19	0	7	7
Cumberland Valley	11	51	10	36	37
FIVCO	24	51	9	29	31
Gateway	8	25	<5	12	15
Green River	7	24	<5	14	17
KIPDA	183	371	15	159	171
Kentucky River	10	19	6	14	15
Lake Cumberland	10	47	11	23	28
Lincoln Trail	25	58	<5	29	26
Northern Kentucky	95	224	13	81	99
Pennyrile	<5	19	<5	15	14
Purchase	<5	18	<5	14	11

¹Schedule V controlled substances were not included due to low counts.





²In accordance with state data release policy, counts less than five are suppressed.

³Drug testing of blood, urine, and/or vitreous fluids.

⁴Drug schedules are not mutually exclusive; decedents may have more than one drug schedule detected.

Table 22. Kentucky Resident Drug Overdose Fatality Counts Involving Specific Drugs by Kentucky Area Development District (ADD), 2017^{1–3}

ADD District	Heroin⁴	Fentanyl ⁴	Heroin⁴ with Fentanyl⁴	Methamphetamine
Barren River	<5	<5	<5	10
Big Sandy	0	<5	0	5
Bluegrass	70	204	54	79
Buffalo Trace	6	16	6	<5
Cumberland Valley	<5	12	<5	28
FIVCO	13	28	12	17
Gateway	<5	15	<5	8
Green River	<5	8	<5	11
KIPDA	131	256	92	140
Kentucky River	<5	<5	<5	8
Lake Cumberland	7	12	<5	25
Lincoln Trail	17	41	16	30
Northern Kentucky	64	161	50	46
Pennyrile	<5	<5	0	6
Purchase	0	<5	0	5

¹In accordance with state data release policy, counts less than five are suppressed.





²Drug testing of blood, urine, and/or vitreous fluids.

³Drugs are not mutually exclusive; decedents may have more than one drug detected.

⁴Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

Figure 6. Kentucky Resident Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016^{1-2}





Figure 7. Kentucky Resident Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017^{1-2}



¹In accordance with state data release policy, rates based on counts less than 10 are suppressed.





²Rates based on counts less than 20 are unstable and should be interpreted with caution.

Figure 8. Kentucky Resident Schedule I-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016^{1-2}





Figure 9. Kentucky Resident Schedule I-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017^{1-2}







²Rates based on counts less than 20 are unstable and should be interpreted with caution.

Figure 10. Kentucky Resident Schedule II-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016^{1-2}





Figure 11. Kentucky Resident Schedule II-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017^{1-2}







²Rates based on counts less than 20 are unstable and should be interpreted with caution.

Figure 12. Kentucky Resident Schedule III-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016^{1-2}





Figure 13. Kentucky Resident Schedule III-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017^{1-2}







²Rates based on counts less than 20 are unstable and should be interpreted with caution.

Figure 14. Kentucky Resident Schedule IV-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016^{1-2}





Figure 15. Kentucky Resident Schedule IV-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017^{1-2}



¹In accordance with state data release policy, rates based on counts less than 10 are suppressed. ²Rates based on counts less than 20 are unstable and should be interpreted with caution.





Figure 16. Kentucky Resident Unscheduled-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016^{1-2}





Figure 17. Kentucky Resident Unscheduled-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017^{1-2}







²Rates based on counts less than 20 are unstable and should be interpreted with caution.

Figure 18. Kentucky Resident Heroin-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016^{1-2}





Figure 19. Kentucky Resident Heroin-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017^{1-2}







²Rates based on counts less than 20 are unstable and should be interpreted with caution.

Figure 20. Kentucky Resident Fentanyl-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016^{1-2}





Figure 21. Kentucky Resident Fentanyl-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017^{1–2}



¹In accordance with state data release policy, rates based on counts less than 10 are suppressed.





²Rates based on counts less than 20 are unstable and should be interpreted with caution.

Figure 22. Kentucky Resident Heroin and Fentanyl-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016^{1-2}





Figure 23. Kentucky Resident Heroin and Fentanyl-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017^{1-2}



²Rates based on counts less than 20 are unstable and should be interpreted with caution.

Produced by the Kentucky Injury Prevention and Research Center, as bona fide agent for t





Figure 24. Kentucky Resident Methamphetamine-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2016^{1-2}





Figure 25. Kentucky Resident Methamphetamine-Involved Drug Overdose Fatality Rates per 100,000 Population by Area Development District, 2017^{1-2}







²Rates based on counts less than 20 are unstable and should be interpreted with caution.

EVIDENCE FOUND AT SCENE AND/OR AUTOPSY OF DRUG OVERDOSE DECEDENTS

Table 23. Most Frequent Drugs Detected in Post-Mortem Toxicology Test Results of Drug Overdose Decedents in Kentucky with Drug Paraphernalia Recovered at Scene and/or Autopsy, 2017¹

	Drug Parapher	Drug Paraphernalia Found?⁵			
	Yes (%)	No/Unknown (%)			
Drug ²⁻⁴	N=401	N=1,052	p-value ⁶		
Fentanyl	303 (75.6%)	516 (49.0%)	<.01		
Morphine ⁷	265 (66.1%)	407 (38.7%)	<.01		
Heroin	147 (36.7%)	197 (18.7%)	<.01		
Methamphetamine	144 (35.9%)	296 (28.1%)	<.01		
Amphetamine	125 (31.2%)	244 (23.2%)	<.01		
Codeine	116 (28.9%)	155 (14.7%)	<.01		
Gabapentin	110 (27.4%)	356 (33.8%)	0.02		
Alprazolam	88 (21.9%)	259 (24.6%)	0.29		
Cocaine	84 (20.9%)	199 (18.9%)	0.38		
THC-COOH	62 (15.5%)	242 (23.0%)	<.01		
Clonazepam	57 (14.2%)	176 (16.7%)	0.24		
Ethanol	52 (13.0%)	186 (17.7%)	0.03		
Oxycodone	30 (7.5%)	186 (17.7%)	<.01		

¹Counts are based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results for that group.





²Detected drugs identified in blood, urine, and/or vitreous fluids.

³Drugs are not mutually exclusive; decedents may have more than one drug detected.

⁴Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

⁵Any reported drug paraphernalia identified from autopsy, coroner investigation, or medical records.

 $^{^6}p$ -value from chi-square test of independence, which tests if a statistical association exists between the presence of drug paraphernalia and a positive finding for the specified drug in post-mortem toxicology.

⁷Morphine may represent pure morphine and/or a metabolite of heroin.

Table 24. Most Frequent Drugs Detected in Post-Mortem Toxicology Test Results of Drug Overdose Decedents in Kentucky with Illicit Drugs Recovered at Scene and/or Autopsy, 2017¹

Illicit Drugs Found?⁵				
	Yes (%)	No/Unknown (%)		
Drug ²⁻⁴	N=286	N=1,167	p-value ⁶	
Fentanyl	210 (73.4%)	609 (52.2%)	<.01	
Morphine ⁷	181 (63.3%)	491 (42.1%)	<.01	
Methamphetamine	103 (36.0%)	337 (28.9%)	0.02	
Heroin	102 (35.7%)	242 (20.7%)	<.01	
Amphetamine	84 (29.4%)	285 (24.4%)	0.08	
Codeine	80 (28.0%)	191 (16.4%)	<.01	
Alprazolam	72 (25.2%)	275 (23.6%)	0.57	
Cocaine	70 (24.5%)	213 (18.3%)	0.02	
Gabapentin	68 (23.8%)	398 (34.1%)	<.01	
THC-COOH	56 (19.6%)	248 (21.3%)	0.53	
Clonazepam	45 (15.7%)	188 (16.1%)	0.88	
Ethanol	44 (15.4%)	194 (16.6%)	0.61	
Oxycodone	24 (8.4%)	192 (16.5%)	<.01	

¹Counts are based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results for that group.





²Detected drugs identified in blood, urine, and/or vitreous fluids.

³Drugs are not mutually exclusive; decedents may have more than one drug detected.

⁴Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

⁵Any reported illicit drugs identified from autopsy, coroner investigation, or medical records.

⁶p-value from chi-square test of independence, which tests if a statistical association exists between the presence of illicit drugs and a positive finding for the specified drug in post-mortem toxicology.

⁷Morphine may represent pure morphine and/or a metabolite of heroin.

Table 25. Most Frequent Drugs Detected in Post-Mortem Toxicology Test Results of Drug Overdose Decedents in Kentucky with Prescription Drugs Recovered at Scene and/or Autopsy, 2017¹

	Prescription D	rugs Found? ⁵	
	Yes (%)	No/Unknown (%)	
Drug ²⁻⁴	N=286	N=1,167	p-value ⁶
Fentanyl	129 (45.1%)	690 (59.1%)	<.01
Gabapentin	116 (40.6%)	350 (30.0%)	<.01
Morphine ⁷	113 (39.5%)	559 (47.9%)	<.01
Methamphetamine	78 (27.3%)	362 (31.0%)	0.22
Alprazolam	75 (26.2%)	272 (23.3%)	0.30
Amphetamine	67 (23.4%)	302 (25.9%)	0.39
Clonazepam	58 (20.3%)	175 (15.0%)	0.03
Oxycodone	53 (18.5%)	163 (14.0%)	0.05
Ethanol	51 (17.8%)	187 (16.0%)	0.46
Heroin	50 (17.5%)	294 (25.2%)	<.01
Codeine	49 (17.1%)	222 (19.0%)	0.46
THC-COOH	48 (16.8%)	256 (21.9%)	0.55
Cocaine	45 (15.7%)	238 (20.4%)	0.07

¹Counts are based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results for that group.





²Detected drugs identified in blood, urine, and/or vitreous fluids.

³Drugs are not mutually exclusive; decedents may have more than one drug detected.

⁴Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

⁵Any reported prescription drugs identified from autopsy, coroner investigation, or medical records.

⁶*p*-value from chi-square test of independence, which tests if a statistical association exists between the presence of prescription drugs found and a positive finding for the specified drug in post-mortem toxicology.

⁷Morphine may represent pure morphine and/or a metabolite of heroin.

Table 26. Drug Overdose Decedents in Kentucky with Nonmedical-Related Needle or Track Marks Identified and the Body Location of the Marks, 2017¹

		Percentage of Decedents with Identified Needle or Track Marks	Percentage of All Decedents
Body Location ^{2–3}	Count	(N=301)	(N=1,561)
Head	<5	*	*
Neck	<5	*	*
Arm	35	11.6%	2.2%
Antecubital Fossa ⁴	197	65.4%	12.6%
Forearm	54	17.9%	3.5%
Wrist	28	9.3%	1.8%
Hand	42	14.0%	2.7%
Breast	0	0.0%	0.0%
Abdomen	<5	*	*
Back	0	0.0%	0.0%
Buttocks	0	0.0%	0.0%
Thigh	5	1.7%	0.3%
Leg	0	0.0%	0.0%
Ankle	<5	*	*
Foot	5	1.7%	0.3%
Other	<5	*	*
Unknown Location	22	7.3%	1.4%

¹In accordance with state data release policy, counts less than five are suppressed. Any number associated with the suppressed count is labeled with an *.





²Body locations of needle/track marks are not mutually exclusive; decedents may have more than one location identified. ³Any reported nonmedical-related needle marks or track marks identified from autopsy, coroner investigation, or medical records. Specific location of the needle and/or track mark(s) are not always provided in the records.

⁴Antecubital fossa is the triangular cavity between the upper arm and forearm located on the anterior surface of the elbow. Produced by the Kentucky Injury Prevention and Research Center, as bona fide agent for the Kentucky Department for Public Health. June 2020. Kentucky data sources: death certificates, Kentucky Office of Vital Statistics, Cabinet for Health and Family Services; post-mortem toxicology records and autopsy reports, Kentucky State Medical Examiner's Office, Justice and Public Safety Cabinet; Kentucky All Schedule Prescription Electronic Reporting, Office of Inspector General, Cabinet for Health and Family Services; and Kentucky coroner investigation reports, county coroners' offices. Data outputs draw from selected DOFSS data sources. Data are provisional and subject to change.

Table 27. Decedent History of Substance Use by Evidence Recovered at Scene and/or Autopsy, 2017

	Decedent History	Decedent History of Substance Use? ³		
	Yes (%)	No/Unknown (%)		
Evidence Recovered ¹⁻²	N=962	N=599		
Drug Paraphernalia Recovered	331 (34.4%)	73 (12.2%)		
Illicit Drugs Recovered	183 (19.0%)	106 (17.7%)		
Prescription Drugs Recovered	226 (23.5%)	62 (10.4%)		

¹Any reported evidence recovered at scene and/or autopsy identified from autopsy, coroner investigation, or medical records. ²Types of evidence recovered are not mutually exclusive; decedents may have more than one type of evidence recovered. ³Any reported history of substance use identified from autopsy, coroner investigation, or medical records.

Table 28. Evidence Recovered at Scene and/or Autopsy that Indicates Route of Administration, 2017¹

Route of Administration ^{2–4}	Count	Percentage ⁵
Evidence of Injection	434	61.82%
Evidence of Ingestion	244	34.76%
Evidence of Snorting	90	12.82%
Evidence of Smoking	37	5.27%
Evidence of Transdermal Application ⁶	<5	*

¹In accordance with state data release policy, counts less than five are suppressed. Any number associated with the suppressed count is labeled with an *.





²Any reported evidence recovered at scene and/or autopsy identified from autopsy, coroner investigation, or medical records.

³Evidence of a route of administration is not unequivocal evidence that a specific route of administration was used for fatal event.

⁴Route of administrations are not mutually exclusive; decedents may have more than one route of administration identified.

⁵Percentage is based on total number of DOFSS drug overdose fatalities with evidence recovered at scene and/or autopsy indicating route of administration, n=702.

⁶Most frequent drugs detected in post-mortem toxicology testing results of drug overdose decedents with evidence of transdermal application were not included due to low count.

Table 29. Most Frequent Drugs Detected in Post-Mortem Toxicology Testing Results of Drug Overdose Decedents in Kentucky with Evidence of Injection, 2017¹

	Evidence of	Evidence of Injection? ⁵		
	Yes (%)	No/Unknown (%)		
Drug ²⁻⁴	N=430	N=1,023	p-value ⁶	
Fentanyl	326 (75.8%)	493 (48.2%)	<.01	
Morphine ⁷	292 (67.9%)	380 (37.1%)	<.01	
Methamphetamine	162 (37.7%)	278 (27.2%)	<.01	
Heroin	150 (34.9%)	194 (19.0%)	<.01	
Amphetamine	143 (33.3%)	226 (22.1%)	<.01	
Gabapentin	132 (30.7%)	334 (32.6%)	0.47	
Codeine	127 (29.5%)	144 (14.1%)	<.01	
Alprazolam	87 (20.2%)	260 (25.4%)	0.03	
Cocaine	86 (20.0%)	197 (19.3%)	0.74	
THC-COOH	71 (16.5%)	233 (22.8%)	<.01	
Clonazepam	62 (14.4%)	171 (16.7%)	0.28	
Ethanol	46 (10.7%)	192 (18.8%)	<.01	
Oxycodone	35 (8.1%)	181 (17.7%)	<.01	

¹Counts are based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results for that group.





²Detected drugs identified in blood, urine, and/or vitreous fluids.

³Drugs are not mutually exclusive; decedents may have more than one drug detected.

⁴Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

⁵Any reported injection evidence identified from autopsy, coroner investigation, or medical records.

⁶p-value from chi-square test of independence, which tests if a statistical association exists between evidence of injection and a positive finding for the specified drug in post-mortem toxicology.

⁷Morphine may represent pure morphine and/or a metabolite of heroin.

Table 30. Most Frequent Drugs Detected in Post-Mortem Toxicology Testing Results of Drug Overdose Decedents in Kentucky with Evidence of Ingestion, 2017¹

	Evidence of		
	Yes (%)	No/Unknown (%)	
Drug ²⁻⁴	N=239	N=1,214	p-value ⁶
Fentanyl	101 (42.3%)	718 (59.1%)	<.01
Gabapentin	93 (38.9%)	373 (30.7%)	0.01
Morphine ⁷	91 (38.1%)	581 (47.9%)	<.01
Methamphetamine	67 (28.0%)	373 (30.7%)	0.41
Alprazolam	65 (27.2%)	282 (23.2%)	0.19
Amphetamine	55 (23.0%)	314 (25.9%)	0.35
Oxycodone	49 (20.5%)	167 (13.8%)	<.01
Clonazepam	47 (19.7%)	186 (15.3%)	0.09
Heroin	42 (17.6%)	302 (24.9%)	0.02
Codeine	41 (17.2%)	230 (18.9%)	0.52
Ethanol	40 (16.7%)	198 (16.3%)	0.87
THC-COOH	37 (15.5%)	267 (22.0%)	0.02
Cocaine	35 (14.6%)	248 (20.4%)	0.04

¹Counts are based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results for that group.





²Detected drugs identified in blood, urine, and/or vitreous fluids.

³Drugs are not mutually exclusive; decedents may have more than one drug detected.

⁴Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

⁵Any reported ingestion evidence identified from autopsy, coroner investigation, or medical records.

⁶p-value from chi-square test of independence, which tests if a statistical association exists between evidence of ingestion and a positive finding for the specified drug in post-mortem toxicology.

⁷Morphine may represent pure morphine and/or a metabolite of heroin.

Table 31. Most Frequent Drugs Detected in Post-Mortem Toxicology Testing Results of Drug Overdose Decedents in Kentucky with Evidence of Snorting, 2017¹

	Evidence of		
	Yes (%)	No/Unknown (%)	
Drug ^{2–4}	N=89	N=1,364	p-value ⁶
Fentanyl	63 (70.8%)	756 (55.4%)	<.01
Morphine ⁷	50 (56.2%)	622 (45.6%)	0.05
Alprazolam	30 (33.7%)	317 (23.2%)	0.02
Gabapentin	27 (30.3%)	439 (32.2%)	0.72
Heroin	27 (30.3%)	317 (23.2%)	0.13
Methamphetamine	25 (28.1%)	415 (30.4%)	0.64
Cocaine	25 (28.1%)	258 (18.9%)	0.03
Codeine	23 (25.8%)	248 (18.2%)	0.07
Ethanol	21 (23.6%)	217 (15.9%)	0.06
THC-COOH	18 (20.2%)	286 (21.0%)	0.87
Amphetamine	16 (18.0%)	353 (25.9%)	0.10
Clonazepam	14 (15.7%)	219 (16.1%)	0.94
Oxycodone	9 (10.1%)	207 (15.2%)	0.19

¹Counts are based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results for that group.





²Detected drugs identified in blood, urine, and/or vitreous fluids.

³Drugs are not mutually exclusive; decedents may have more than one drug detected.

⁴Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

⁵Any reported snorting evidence identified from autopsy, coroner investigation, or medical records.

⁶p-value from chi-square test of independence, which tests if a statistical association exists between evidence of snorting and a positive finding for the specified drug in post-mortem toxicology.

⁷Morphine may represent pure morphine and/or a metabolite of heroin.

Table 32. Most Frequent Drugs Detected in Post-Mortem Toxicology Testing Results of Drug Overdose Decedents in Kentucky with Evidence of Smoking, 2017^{1–2}

	Evidence of		
	Yes (%)	No/Unknown (%)	
Drug ³⁻⁵	N=37	N=1,416	p-value ⁷
Fentanyl	21 (56.8%)	798 (56.4%)	0.96
Cocaine	18 (48.6%)	265 (18.7%)	<.01
Methamphetamine	12 (32.4%)	428 (30.2%)	0.77
Gabapentin	10 (27.0%)	456 (32.2%)	0.51
Morphine ⁷	9 (24.3%)	663 (46.8%)	<.01
Amphetamine	8 (21.6%)	361 (25.5%)	0.59
Clonazepam	8 (21.6%)	225 (15.9%)	0.35
THC-COOH	7 (18.9%)	297 (21.0%)	0.76
Alprazolam	6 (16.2%)	341 (24.1%)	0.27
Heroin	6 (16.2%)	338 (23.9%)	0.28
Codeine	<5 (*)	*	0.21
Ethanol	<5 (*)	*	0.07
Oxycodone	<5 (*)	*	0.10

¹Counts are based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results for that group.





²In accordance with state data release policy, counts less than five are suppressed. Any number associated with the suppressed count is labeled with an *.

³Detected drugs identified in blood, urine, and/or vitreous fluids.

⁴Drugs are not mutually exclusive; decedents may have more than one drug detected.

⁵Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

⁶Any reported smoking evidence identified from autopsy, coroner investigation, or medical records.

⁷p-value from chi-square test of independence, which tests if a statistical association exists between evidence of smoking and a positive finding for the specified drug in post-mortem toxicology.

⁸Morphine may represent pure morphine and/or a metabolite of heroin.

Table 33. Top Identifiable Prescription and Over-the-Counter (OTC) Drugs Found at Scene and/or at Autopsy Among Drug Overdose Decedents in Kentucky, 2017

			Percent Change From
Prescription/OTC ¹⁻³	2017 Count	2017 Percentage ⁴	2016-20175
Gabapentin	55	26.44%	-26.67%
Hydrocodone	30	14.42%	-21.05%
Alprazolam	30	14.42%	-28.57%
Oxycodone	26	12.50%	-48.00%
Lisinopril	23	11.06%	-32.35%
Promethazine	15	7.21%	66.67%
Amitriptyline	15	7.21%	7.14%
Omeprazole	15	7.21%	-16.67%
Trazodone	15	7.21%	-16.67%
Bupropion	14	6.73%	250.00%
Metoprolol	14	6.73%	-22.22%
Tizanidine	13	6.25%	18.18%
Clonazepam	13	6.25%	-56.67%
Fluoxetine	12	5.77%	9.09%
Amlodipine	11	5.29%	83.33%
Quetiapine	11	5.29%	-63.33%
Levothyroxine	10	4.81%	100.00%
Cyclobenzaprine	10	4.81%	-9.09%
Citalopram	10	4.81%	-23.08%
Venlafaxine	10	4.81%	-28.57%

¹Prescriptions and OTC drugs are not mutually exclusive; decedents may have more than one prescription drug found at scene and/or autopsy.





²Any reported prescription and OTC drugs at scene and/or autopsy identified from autopsy, coroner investigation, or medical records.


³Prescription and OTC drugs found at scene and/or autopsy do not signify if the decedent's post-mortem toxicology was positive for said drug or if said drug was tested for.

⁴Percentage is based on total number of DOFSS drug overdose fatalities with a named prescription/OTC drug found at scene and/or autopsy, n=208. Reports of evidence of pills or pill bottles without any identifying feature were excluded from this analysis.

⁵Percent Change represents the change in individual drug frequency from 2016 to 2017.

MEDICAL AND SOCIAL HISTORY OF DRUG OVERDOSE DECEDENTS

Figure 26. Other Significant Medical Conditions Contributing to Death of Drug Overdose Decedents in Kentucky, 2017^{1-4}



¹Other significant conditions contributing to death are not mutually exclusive; deaths may be counted in more than one applicable category.

²Of 1,561 Kentucky drug overdose decedents, 381 decedents had other significant condition(s) contributing to death listed on death certificate and/or autopsy report.

³Mechanisms of death recorded on death certificate as a significant condition contributing to death were not included.

⁴"Other" category refers to all low-count significant conditions contributing to death.





Table 34. Medical Conditions of Drug Overdose Decedents in Kentucky, 2017

Medical Condition ¹⁻³	Count	Percentage ⁴
Diseases of the Circulatory System		
Heart Disease		
Essential (Primary) Hypertension	195	12.5%
Cardiomegaly	68	4.4%
Atherosclerosis	39	2.5%
Heart Failure	33	2.1%
High Blood Pressure, Without Diagnosis of Hypertension	22	1.4%
Ischemic Heart Disease	14	0.9%
Previous Myocardial Infarction	9	0.6%
Atrial Fibrillation and Flutter	9	0.6%
Heart Valve Disorders	9	0.6%
Other and Unspecified Heart Diseases	38	2.4%
Cerebral Infarction	12	0.8%
Venous and Arterial Embolism and Thrombosis	7	0.4%
Other and Unspecified Circulatory System Diseases	13	0.8%
Diseases of the Respiratory System		
Chronic Obstructive Pulmonary Disease	81	5.2%
Asthma	34	2.2%
Bronchitis, Pneumonia, and Upper Respiratory Infection	19	1.2%
Emphysema	17	1.1%
Shortness of Breath	11	0.7%
Other and Unspecified Respiratory Disorders	14	0.9%
Diseases of the Digestive System		
Diseases of the Esophagus, Stomach, and Duodenum		
Gastro-Esophageal Reflux Disease	25	1.6%
Other and Unspecified Diseases of the Esophagus, Stomach, and Duodenum	8	0.5%
Liver Disease		
Cirrhosis of the Liver	8	0.5%
Other and Unspecified Diseases of the Liver	22	1.4%
Disorders of the Gallbladder, Biliary Tract, and Pancreas	19	1.2%
Diseases of the Intestines	14	0.9%
Nausea, Heartburn, Vomiting, Constipation, and Diarrhea	8	0.5%
Other and Unspecified Diseases of the Digestive System	6	0.4%
Diseases of the Skin and Subcutaneous Tissue	9	0.6%
Diseases of the Blood and Blood-Forming Organs	10	0.6%





Table 34. Medical Conditions of Drug Overdose Decedents in Kentucky, 2017–continued

Medical Condition ^{1–3}	Count	Percentage ⁴
Diseases of the Genitourinary System		
Kidney Disease		
Chronic Kidney Disease	24	1.5%
Other and Unspecified Diseases of the Kidney	10	0.7%
Other and Unspecified Diseases of the Genitourinary System	11	0.7%
Endocrine, Nutritional, and Metabolic Diseases		
Diabetes Mellitus	102	6.5%
Overweight and Obesity	98	6.3%
Metabolic Diseases		
Hyperlipidemia	22	1.4%
Hypercholesterolemia	5	0.3%
Disorders of the Thyroid Gland	14	0.9%
Other and Unspecified Endocrine, Nutritional, and Metabolic Disorders	13	0.8%
Diseases of the Musculoskeletal System, Connective Tissue, and Nervous System		
Nervous System		
Epilepsy and Recurrent Seizures	51	3.3%
Migraine and Headache	18	1.2%
Sleep Apnea	16	1.0%
Insomnia	13	0.8%
Neuropathies	8	0.5%
Other and Unspecified Disorders of the Nervous System	13	0.8%
Musculoskeletal System and Connective Tissue		
Dorsalgia	60	3.8%
Pain in Joints and Soft Tissue	48	3.1%
Osteoarthritis	16	1.0%
Diseases of Vertebrae and Intervertebral Discs	13	0.8%
Other and Unspecified Disorders of the Musculoskeletal System and Connective	11	0.7%
Tissue	2.5	. =
Acute Pain, Not Elsewhere Classified	26	1.7%
Chronic Pain, Not Elsewhere Classified	19	1.2%
Chronic Pain Syndrome	12	0.8%
Mental, Behavioral, and Neurodevelopmental Disorders		
Substance Use Disorders	202	25.001
Opioid-Related Disorders	393	25.2%
Alcohol-Related Disorders	153	9.8%
Nicotine Dependence	115	7.4%
Other Stimulant-Related Disorders (Excludes Cocaine)	79	5.1%
Cocaine-Related Disorders	56	3.6%





Table 34. Medical Conditions of Drug Overdose Decedents in Kentucky, 2017–continued

2.9% 1.9% 31.4% 8.1% 3.9%
31.4% 8.1% 3.9%
8.1% 3.9%
3.9%
2.3%
0.8%
0.5%
3.1%
0.3%
2.2%
4.9%
0.8%
0.4%
1.5%
1.6%
1.0%
0.7%
1.4%
1.8%
1.1%
0.5%
0.4%
0.6%
1.0%

¹Any reported medical condition identified from death certificate, autopsy, coroner investigation, or medical records.






²Medical conditions were classified using ICD-10-CM diagnoses codes and later organized into concise categories.

³Medical conditions are not mutually exclusive; death may be counted in more than one applicable category.

⁴Percentage is based on total number of DOFSS drug overdose fatalities, n=1,561.

Figure 27. Body Mass Index (BMI) Range for Drug Overdose Decedents in Kentucky, 2017¹



¹BMI information was available for 45.8% of total drug overdose decedent cases (715/1,561). BMI information was unavailable for most cases that did not have an autopsy performed.

Produced by the Kentucky Injury Prevention and Research Center, as bona fide agent for the Kentucky Department for Public Health. June 2020. Kentucky data sources: death certificates, Kentucky Office of Vital Statistics, Cabinet for Health and Family Services; post-mortem toxicology records and autopsy reports, Kentucky State Medical Examiner's Office, Justice and Public Safety Cabinet; Kentucky All Schedule Prescription Electronic Reporting, Office of Inspector General, Cabinet for Health and Family Services; and Kentucky coroner investigation reports, county coroners' offices. Data outputs draw from selected DOFSS data sources. Data are provisional and subject to change.

Table 35. Drug Overdose Decedent Body Mass Index (BMI) Percentiles

BMI Percentiles						
5 th	10 th	25 th	50 th	75 th	90 th	95 th
percentile	percentile	percentile	percentile	percentile	percentile	percentile
20	21	24	28	32	37	39





²Percentages based on total number of drug overdose decedents with BMI information available (n=715).

Table 36. Circumstances and History of Drug Overdose Decedents in Kentucky, 2017

Circumstance ¹	Count	Percentage
Fatal Overdose Event		
Bystander(s) Present at Time of Overdose ²	451	28.9%
1 bystander present	195	12.5%
Multiple bystanders present	119	7.6%
Bystanders present, unknown number	137	8.8%
Evidence of Rapid Overdose ³	139	8.9%
Naloxone Administered	136	8.7%
Treatment		
Ever Treated for Substance Use	127	8.1%
Current Substance Use Treatment	36	2.3%
Ever Treated for Mental Health Issues	25	1.6%
Current Mental Health Treatment	18	1.2%
Recent Release ⁴ from Residential Substance Use Treatment	43	2.8%
Recent Release ⁴ from Hospital/Emergency Room ⁵	61	3.9%
Substance Use Relapse	199	12.7%
Relapse occurred < 2 weeks prior to fatal overdose	45	2.9%
Relapse occurred > 2 weeks to < 3 months prior to fatal overdose	7	0.4%
Relapse mentioned, timing unclear	147	9.4%
Incarceration		
Previous Incarceration	76	4.9%
Recent Release ⁴ from Jail, Prison	48	3.1%
Currently Incarcerated or on House Arrest	29	1.9%
History		
History of Substance Use	962	61.6%
History of Life Change, Crisis, or Traumatic Event Within Last Month ⁶	227	14.5%
History of Mental Illness	193	12.4%
History of Previous Overdose	126	8.1%
Previous OD within the last month	40	2.6%
Previous OD occurred between a month and a year ago	25	1.6%
Previous OD occurred more than a year ago	7	0.4%
Previous OD, timing unknown	54	3.5%
History of Chronic Pain	124	7.9%





Table 36. Circumstances and History of Drug Overdose Decedents in Kentucky, 2017–continued

Circumstance ¹	Count	Percentage
Suicide-Related		
History of Suicidal Ideations	34	2.2%
Previous Suicide Attempts	22	1.4%
Suicide Intent Disclosed to Another Person	21	1.3%
Suicide Note Found at Time of Fatal Overdose	15	1.0%

¹Any reported circumstance history identified from autopsy, coroner investigation, or medical records.





²"Bystander" is a person or persons present at the same location as decedent at the time of the fatal overdose. That person may have not witnessed drug use or been in the same room as the decedent at the time of death.

³"Rapid overdose" indicates an overdose occurring within a short timeframe after drug use.

⁴"Recent release" is defined as having been released from the institution within the last month or if no date of admission or release is provided yet phrasing of language within documentation indicates release was comparatively close to present.

⁵Hospital or ER visit may have been related to any medical condition or event; it is not limited to overdose/substance use.

⁶"Crisis" is any event, life change, or traumatic event that occurred within the last month prior to fatal drug overdose. This may include: substance use relapse, job changes, housing issues, victim of a crime, death of friend or family, etc.

Table 37. Most Frequent Drugs Detected in Post-Mortem Toxicology Test Results of Drug Overdose Decedents in Kentucky with History of Substance Use, 2017¹

	Decedent History of Substance Use?5		
	Yes (%)	No/Unknown (%)	6
Drug ²⁻⁴	N=935	N=518	p-value ⁶
Fentanyl	608 (65.0%)	211 (40.7%)	<.01
Morphine ⁷	510 (54.5%)	162 (31.3%)	<.01
Methamphetamine	290 (31.0%)	150 (29.0%)	0.40
Gabapentin	280 (29.9%)	186 (35.9%)	0.02
Heroin	262 (28.0%)	82 (15.8%)	<.01
Amphetamine	247 (26.4%)	122 (23.6%)	0.23
Alprazolam	217 (23.2%)	130 (25.1%)	0.42
Codeine	204 (21.8%)	67 (12.9%)	<.01
Cocaine	202 (21.6%)	80 (15.4%)	<.01
THC-COOH	196 (21.0%)	108 (20.8%)	0.96
Ethanol	136 (14.5%)	102 (19.7%)	<.01
Clonazepam	135 (14.4%)	98 (18.9%)	0.03
Oxycodone	103 (11.0%)	113 (21.8%)	<.01

¹Counts are based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results for each group.





²Detected drugs identified in blood, urine, and/or vitreous fluids.

³Drugs are not mutually exclusive; decedents may have more than one drug detected.


⁴Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

⁵Any reported history of substance use identified from autopsy, coroner investigation, or medical records.

 $^{^6}p$ -value from chi-square test of independence, which tests if a statistical association exists between decedent history of substance use and a positive finding for the specified drug in post-mortem toxicology.

⁷Morphine may represent pure morphine and/or a metabolite of heroin.

Figure 28. Demographics of Drug Overdose Decedents in Kentucky with History of Substance Use, 2017



¹Any reported history of substance use identified from autopsy, coroner investigation, or medical records.





Table 38. Suicide and Accidental Manners of Death Among Drug Overdose Decedents in Kentucky with History of Substance Use, 2017

	Decedent Hi	Decedent History of Substance Use?	
Manner of Death	Yes (%)	No/Unknown (%)	
Suicide (n=60)	14 (23.3%)	46 (76.7%)	
Accidental (n=1,397)	902 (64.6%)	495 (35.4%)	

¹Any reported history of substance use identified from autopsy, coroner investigation, or medical records.

Produced by the Kentucky Injury Prevention and Research Center, as bona fide agent for the Kentucky Department for Public Health. June 2020. Kentucky data sources: death certificates, Kentucky Office of Vital Statistics, Cabinet for Health and Family Services; post-mortem toxicology records and autopsy reports, Kentucky State Medical Examiner's Office, Justice and Public Safety Cabinet; Kentucky All Schedule Prescription Electronic Reporting, Office of Inspector General, Cabinet for Health and Family Services; and Kentucky coroner investigation reports, county coroners' offices. Data outputs draw from selected DOFSS data sources. Data are provisional and subject to change.

Table 39. Opioid-Involved Drug Overdoses Among Drug Overdose Decedents in Kentucky with History of Pain, 2017^{1-2}

	Type of Overdose		
	Opioid-involved Fatal		
Type of Pain ³⁻⁴	Overdose (n=1,273)	Other Fatal Overdose (n=180)	
Chronic Pain	110 (8.6%)	11 (6.11%)	
Acute Pain	30 (2.4%)	6 (3.3%)	
Pain, Not Otherwise Specified	44 (3.5%)	<5 (*)	

¹Counts are based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results, n=1,453.





²In accordance with state data release policy, counts less than five are suppressed. Any number associated with the suppressed count is labeled with an *.

³Any reported history of pain identified by autopsy, coroner investigation, or medical records.

⁴Types of pain are not mutually exclusive; decedents may have more than one type of pain diagnosed.

Table 40. Most Frequent Drugs Detected in Post-Mortem Toxicology Test Results of Drug Overdose Decedents in Kentucky with History of Mental Illness, 2017¹

	Decedent History of Mental Illness? ⁵		
2-4	Yes (%)	No/Unknown (%)	p-value ⁶
Drug ²⁻⁴	N=181	N=1,272	p-value
Fentanyl	74 (40.9%)	745 (58.6%)	<.01
Gabapentin	62 (34.3%)	404 (31.8%)	0.50
Morphine ⁷	55 (30.4%)	617 (48.5%)	<.01
Alprazolam	48 (26.5%)	299 (23.5%)	0.37
Clonazepam	47 (26.0%)	186 (14.6%)	<.01
Cocaine	33 (18.2%)	250 (19.7%)	0.65
Codeine	33 (18.2%)	249 (19.6%)	0.02
Ethanol	32 (17.7%)	206 (16.2%)	0.61
Methamphetamine	31 (17.1%)	409 (32.2%)	<.01
THC-COOH	28 (15.5%)	276 (21.7%)	0.05
Amphetamine	26 (14.4%)	343 (27.0%)	<.01
Heroin	26 (14.4%)	318 (25.0%)	<.01
Oxycodone	23 (12.7%)	193 (15.2%)	0.38

¹Counts are based on total number of DOFSS drug overdose fatalities with at least one drug present in toxicology results for each group.





²Detected drugs identified in blood, urine, and/or vitreous fluids.

³Drugs are not mutually exclusive; decedents may have more than one drug detected.

⁴Parent drugs with unique metabolites are classified and represented by the parent drug only. All instances of the parent drug and unique metabolite(s) are counted once per decedent and labeled as the parent drug. This is true for all drugs with unique metabolites except for THC due to the lengthy metabolism of THC-COOH. A list of unique metabolites for each parent drug is found in Definitions.

⁵Any reported history of mental illness identified by autopsy, coroner investigation, or medical records.

⁶*p*-value from chi-square test of independence, which tests if a statistical association exists between decedent history of mental illness and a positive finding for the specified drug in post-mortem toxicology.

⁷Morphine may represent pure morphine and/or a metabolite of heroin.




Figure 29. Demographics of Drug Overdose Decedents in Kentucky with History of Mental Illness, 2017^{1–2}

¹Any reported history of mental illness identified by autopsy, coroner investigation, or medical records.





²In accordance with state data release policy, counts less than five are suppressed. Any number associated with the suppressed count is labeled with an *.

Table 41. Suicide and Accidental Manners of Death Among Drug Overdose Decedents in Kentucky with History of Mental Illness, 2017

	Decede	Decedent History of Mental Illness? ¹	
Manner of Death	Yes (%)	No/Unknown (%)	
Accidental (n=1,397)	143 (10.2%)	1,254 (89.8%)	
Suicide (n=60)	34 (56.7%)	26 (43.3%)	

¹Any reported history of mental illness identified by autopsy, coroner investigation, or medical records.





PRESCRIPTION DRUG MONITORING PROGRAM (PDMP) HISTORY OF DRUG OVERDOSE DECEDENTS

Table 42. Most Frequent Schedule II–V Controlled Substances Dispensed to 2017 Drug Overdose Decedents in Kentucky, Three-Year Period Prior to Death Year (1/1/2015–12/31/2017)

	Total Number of Prescriptions Dispensed Within Three-Year Period	Number of Decedents with Prescription Dispensed Within Three-Year Period	Average Number of Prescriptions Dispensed to 2017 Drug Overdose Decedents Within Three-Year Period Prior
Generic Drug Name ¹	Prior to Death ²	Prior to Death ³	to Death
Hydrocodone	5,127 (19.3%)	691 (68.1%)	7.4
Oxycodone	4,456 (16.8%)	488 (48.1%)	9.1
Buprenorphine	3,864 (14.5%)	223 (22.0%)	17.3
Alprazolam	2,491 (9.4%)	168 (16.6%)	14.8
Clonazepam	2,412 (9.1%)	179 (17.6%)	13.5
Zolpidem	1,108 (4.2%)	89 (8.8%)	12.4
Diazepam	1,076 (4.0%)	122 (12.0%)	8.8
Tramadol	908 (3.4%)	233 (23.0%)	3.9
Pregabalin	741 (2.8%)	65 (6.4%)	11.4
Amphetamine	500 (1.9%)	33 (3.3%)	15.2
Morphine	462 (1.7%)	50 (4.9%)	9.2
Lorazepam	449 (1.7%)	73 (7.2%)	6.2
Gabapentin	428 (1.6%)	152 (15.0%)	2.8
Butalbital	383 (1.4%)	56 (5.5%)	6.8
Codeine	353 (1.3%)	158 (15.6%)	2.2
Methadone	301 (1.1%)	26 (2.6%)	11.6
Fentanyl	220 (0.8%)	23 (2.3%)	9.6
Carisoprodol	197 (0.7%)	16 (1.6%)	12.3
Temazepam	128 (0.5%)	12 (1.2%)	10.7
Testosterone	114 (0.4%)	14 (1.4%)	8.1

¹Prescription may be for any formulation of the drug listed, including combination products that include non-controlled substances. Prescriptions may be for generic, name brand, or specialized release version of the drug. Prescriptions are not mutually exclusive; decedents may have prescriptions for multiple drugs.





²Includes every occurrence of the prescribed drug for each decedent within the stated timeframe; decedents may have multiple prescriptions dispensed for a single drug. Percentage is based on the total number of prescriptions dispensed to DOFSS drug overdose fatalities within three-year period, n=26,584.

³Multiple prescriptions for the same drug are counted as one prescription drug incident per decedent. Percentage is based on total number of DOFSS drug overdose fatalities with KASPER PDMP data available, n=1,015.

Table 43. Number of Drug Overdose Decedents with an Active Schedule II–V Prescription Dispensed for Drug(s) Detected in Post-Mortem Toxicology, Prescription Active 180 Days Prior to Death, 30 Days Prior to Death, and Day of Death^{1–2}

Selected Drug Types Detected in Toxicology ³⁻⁴	Number of Drug Overdose Decedents with Prescription Active Within 180 Days Prior to Death	Number of Drug Overdose Decedents with Prescription Active Within 30 Days Prior to Death	Number of Drug Overdose Decedents with Prescription Active on Day of Death
Overall	356 (35.1%)	305 (30.0%)	271 (26.7%)
Opioids (Excluding		, ,	, ,
Buprenorphine/Naloxone)	226 (22.3%)	181 (17.8%)	146 (14.4%)
Benzodiazepines	173 (17.0%)	156 (15.4%)	139 (13.7%)
Stimulants	9 (0.9%)	7 (0.7%)	5 (0.5%)
Gabapentin	81 (8.0%)	73 (7.2%)	69 (6.8%)

¹This analyses is unable to determine if the drug detected in the post-mortem toxicology result is in fact the drug dispensed to the decedent.





²Percentages are based on total number of DOFSS drug overdose fatalities with KASPER PDMP data available, n=1,015.

³Drug testing of blood, urine, and/or vitreous fluids.

⁴Drug types are not mutually exclusive; decedents may have multiple drug types detected with an active prescription.

Table 44. Most Frequent Schedule II–V Opioids (Excluding Buprenorphine/Naloxone) Dispensed to 2017 Drug Overdose Decedents with Illicit Opioids Detected in Post-Mortem Toxicology, Three-Year Period (1/1/2015–12/31/2017)¹

	Total Number of	Number of Illicit	Average Number of
	Prescriptions Dispensed	Opioid Overdose	Prescriptions Dispensed to
	to Illicit Opioid	Decedents with	Illicit Opioid Overdose
	Overdose Decedents	Prescription Within	Decedents with Prescription
	Within Three-Year	Three-Year Period	Within Three-Year Period
Generic Drug Name ²	Period Prior to Death ³	Prior to Death⁴	Prior to Death
Hydrocodone	1,975 (44.0%)	361 (66.0%)	5.5
Oxycodone	1,704 (37.9%)	261 (47.7%)	6.5
Tramadol	309 (6.9%)	105 (19.2%)	2.9
Methadone	125 (2.8%)	10 (1.8%)	12.5
Codeine	124 (2.8%)	69 (12.6%)	1.8
Morphine	123 (2.7%)	20 (3.7%)	6.2
Fentanyl	66 (1.5%)	8 (1.5%)	8.3
Oxymorphone	37 (0.8%)	<5 (*)	-
Meperidine	16 (0.4%)	<5 (*)	-
Hydromorphone	10 (0.2%)	5 (0.9%)	2.0
Pentazocine	<5 (*)	<5 (*)	

¹In accordance with state data release policy, counts less than five are suppressed. Any number directly associated with the suppressed count is labeled with an *. A count greater than five or an associated number may not be reported if that value would disclose a suppressed value; these are labeled with a -.

³Includes every occurrence of the prescribed drug for each decedent within the stated timeframe; decedents may have multiple prescriptions dispensed for a single drug. Percentage is based on the total number of opioid prescriptions dispensed to DOFSS drug overdose fatalities with illicit opioids detected in post-mortem toxicology within three-year period, n=4,491.

⁴Multiple prescriptions for the same drug are counted as one prescription drug incident per decedent. Percentage is based on total number of DOFSS drug overdose fatalities with illicit opioids detected in post-mortem toxicology with KASPER PDMP data available, n=547.





²Prescriptions may be for any formulation of the drug listed, including combination products that include non-controlled substances. Prescriptions may be for generic, name brand, or specialized release version of the drug. Prescriptions are not mutually exclusive; decedents may have prescriptions for multiple drugs.

Table 45. Number of Drug Overdose Decedents with Illicit Opioids Detected in Post-Mortem Toxicology with an Active Schedule II–V Opioid Prescription (Excluding Buprenorphine/Naloxone), Prescription Active 180 Days Prior to Death, 30 Days Prior to Death, and Day of Death^{1–2}

	Number of Illicit Opioid Overdose Decedents with Opioid Prescription ^{3–5}
Opioid Prescription Active Within 180 Days Prior to Death	212 (38.5%)
Opioid Prescription Active Within 30 Days Prior to Death	102 (18.5 %)
Opioid Prescription Active on Day of Death	55 (10.0%)

¹This analyses is unable to determine if the drug detected in the post-mortem toxicology result is in fact the drug dispensed to the decedent.





²Opioid prescriptions excluded naloxone and buprenorphine.

³Percentage is based on total number of DOFSS drug overdose fatalities with illicit opioids detected in post-mortem toxicology with KASPER PDMP data available, n=547.

⁴Drug testing of blood, urine, and/or vitreous fluids.

⁵Drug types are not mutually exclusive; decedents may have multiple drug types detected with an active prescription.

Table 46. Most Frequent Schedule II–V Controlled Substances Detected in Post-Mortem Toxicology of 2017 Drug Overdose Decedents in Kentucky Without a Prescription Identified, Three-Year Period Prior to Death Year (1/1/2015–12/31/2017)¹

Drug ²⁻³	Count	Percentage ⁴
Fentanyl	493	48.6%
Morphine	382	37.6%
Gabapentin	266	26.2%
Amphetamine	217	21.4%
Alprazolam	154	15.2%
Nordiazepam	55	5.4%
Temazepam	50	4.9%
Methadone	36	3.5%
Buprenorphine	35	3.4%
Oxymorphone	34	3.3%
Hydromorphone	28	2.8%
Diazepam	27	2.7%
Hydrocodone	21	2.1%
Tramadol	21	2.1%
Lorazepam	15	1.5%

¹This analyses is unable to determine the original source of the drug detected in the post-mortem toxicology result. The drug may be legally dispensed, diverted, and/or clandestinely produced.





²Drug testing of blood, urine, and/or vitreous fluids.

³Drug types are not mutually exclusive; decedents may have multiple drug types detected with an active prescription.

⁴Percentage is based on total number of DOFSS drug overdose fatalities with KASPER PDMP data available, n=1,015.

DOFSS QUALITY CONTROL MEASURES

Table 47. Number and Percentage of Drug Overdose Fatality Coroner Investigation Reports Received for DOFSS, 2015–2017

Investigation Report Received?	Yes (%) ¹	No (%)
2015	995 (79.4%)	258 (20.6%)
2016	1,172 (81.3%)	269 (18.7%)
2017	1,234 (79.5%)	318 (20.5%)

¹Kentucky residents who died out of state were excluded from coroner request analysis.

Produced by the Kentucky Injury Prevention and Research Center, as bona fide agent for the Kentucky Department for Public Health. June 2020. Kentucky data sources: death certificates, Kentucky Office of Vital Statistics, Cabinet for Health and Family Services; post-mortem toxicology records and autopsy reports, Kentucky State Medical Examiner's Office, Justice and Public Safety Cabinet; Kentucky All Schedule Prescription Electronic Reporting, Office of Inspector General, Cabinet for Health and Family Services; and Kentucky coroner investigation reports, county coroners' offices. Data outputs draw from selected DOFSS data sources. Data are provisional and subject to change.

Table 48. Identification of Specific Drug Involvement Using a Multi-Source Surveillance System, 2016–2017¹

	Number of Drug Overdose	Number of Drug Overdose	
	Fatalities with Specific Drugs	Fatalities with Specific Drugs	% Change
Data Source(s) Used	Identified, 2016, N=1,457 (%)	Identified, 2017, N=1,561 (%)	from 2016
Death Certificate	1,190 (81.7%)	1,389 (89.0%)	16.7%
Death Certificate			
Autopsy Report	1,310 (89.9%)	1,444 (92.5%)	10.2%
Death Certificate			
Autopsy Report			
Toxicology Report	1,418 (97.3%)	1,518 (97.2%)	7.1%
Death Certificate			
 Autopsy Report 			
Toxicology Report			
• Coroner Report	1,419 (97.4%)	1,521 (97.4%)	7.2%

¹The additive value of using a comprehensive surveillance system with multiple data sources, such as the Kentucky Drug Overdose Fatality Surveillance System, to identify specific drug involvement in overdose fatalities.



